


Gynecologic Health Care 4th Edition PDF Scanned searchable

Visit the link below to download the full version of the ebook

[DOWNLOAD NOW](#)



Scan to Download
or Type the Link

ebook.ac/gynecologic4e

FOURTH EDITION

GYNECOLOGIC HEALTH CARE

WITH AN INTRODUCTION TO PRENATAL AND
POSTPARTUM CARE



KERRI DURNELL SCHUILING

FRANCES E. LIKIS

FOURTH EDITION

GYNECOLOGIC HEALTH CARE

WITH AN INTRODUCTION TO PRENATAL AND
POSTPARTUM CARE

**KERRI DURNELL SCHUILING, PHD, NP, CNM,
FACNM, FAAN**

Provost and Vice President of Academic Affairs
Distinguished Professor
Northern Michigan University
Marquette, Michigan
Founding Co-Editor-in-Chief
International Journal of Childbirth

FRANCES E. LIKIS, DRPH, NP, CNM, FACNM, FAAN

Editor-in-Chief
Journal of Midwifery & Women's Health
Adjunct Assistant Professor of Nursing
Vanderbilt University
Nashville, Tennessee



JONES & BARTLETT
LEARNING



World Headquarters
Jones & Bartlett Learning
5 Wall Street
Burlington, MA 01803
978-443-5000
info@jblearning.com
www.jblearning.com

Jones & Bartlett Learning books and products are available through most bookstores and online booksellers. To contact Jones & Bartlett Learning directly, call 800-832-0034, fax 978-443-8000, or visit our website, www.jblearning.com.

Substantial discounts on bulk quantities of Jones & Bartlett Learning publications are available to corporations, professional associations, and other qualified organizations. For details and specific discount information, contact the special sales department at Jones & Bartlett Learning via the above contact information or send an email to specialsales@jblearning.com.

Copyright © 2022 by Jones & Bartlett Learning, LLC, an Ascend Learning Company

All rights reserved. No part of the material protected by this copyright may be reproduced or utilized in any form, electronic or mechanical, including photocopying, recording, or by any information storage and retrieval system, without written permission from the copyright owner.

The content, statements, views, and opinions herein are the sole expression of the respective authors and not that of Jones & Bartlett Learning, LLC. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not constitute or imply its endorsement or recommendation by Jones & Bartlett Learning, LLC and such reference shall not be used for advertising or product endorsement purposes. All trademarks displayed are the trademarks of the parties noted herein. *Gynecologic Health Care: With an Introduction to Prenatal and Postpartum Care, Fourth Edition* is an independent publication and has not been authorized, sponsored, or otherwise approved by the owners of the trademarks or service marks referenced in this product.

There may be images in this book that feature models; these models do not necessarily endorse, represent, or participate in the activities represented in the images. Any screenshots in this product are for educational and instructive purposes only. Any individuals and scenarios featured in the case studies throughout this product may be real or fictitious, but are used for instructional purposes only.

The authors, editor, and publisher have made every effort to provide accurate information. However, they are not responsible for errors, omissions, or for any outcomes related to the use of the contents of this book and take no responsibility for the use of the products and procedures described. Treatments and side effects described in this book may not be applicable to all people; likewise, some people may require a dose or experience a side effect that is not described herein. Drugs and medical devices are discussed that may have limited availability controlled by the Food and Drug Administration (FDA) for use only in a research study or clinical trial. Research, clinical practice, and government regulations often change the accepted standard in this field. When consideration is being given to use of any drug in the clinical setting, the health care provider or reader is responsible for determining FDA status of the drug, reading the package insert, and reviewing prescribing information for the most up-to-date recommendations on dose, precautions, and contraindications, and determining the appropriate usage for the product. This is especially important in the case of drugs that are new or seldom used.

Production Credits

VP, Product Management: Amanda Martin
Director of Product Management: Matthew Kane
Product Manager: Joanna Gallant
Product Assistant: Melina Leon
Senior Project Specialist: Vanessa Richards
Project Specialist: John Fuller
Manager, Project Management: Kristen Rogers
Digital Project Specialist: Rachel DiMaggio
Senior Marketing Manager: Lindsay White
Product Fulfillment Manager: Wendy Kilborn
Composition: S4Carlisle Publishing Services

Cover Design: Michael O'Donnell
Senior Media Development Editor: Troy Liston
Rights & Permissions Manager: John Rusk

Cover Image: Symbol: The symbol on the cover is adapted from The Changer by K Robins and is used with the permission of K Robins Designs. The editors are very grateful to K Robins for allowing us to adapt her design for our cover, and we encourage readers to visit www.krobinsdesigns.com where The Changer and other symbols are available as pendants. Background: © Wall to wall/Shutterstock.
Printing and Binding: Sheridan Books

Library of Congress Cataloging-in-Publication Data

Names: Likis, Frances E., editor. | Schuiling, Kerri Durnell, editor.
Title: Gynecologic health care : with an introduction to prenatal and postpartum care / [edited by] Frances E. Likis, Kerri Durnell Schuiling.
Other titles: Women's gynecologic health.
Description: Fourth edition. | Burlington, Massachusetts : Jones & Bartlett Learning, [2022] | Preceded by Women's gynecologic health / [edited by] Kerri Durnell Schuiling, Frances E. Likis. Third edition. [2017] | Includes bibliographical references and index.
Identifiers: LCCN 2020000333 | ISBN 9781284182347 (paperback)
Subjects: MESH: Genital Diseases, Female | Reproductive Physiological Phenomena | Prenatal Care | Women's Health
Classification: LCC RG110 | NLM WP 140 | DDC 618.1--dc23
LC record available at <https://lccn.loc.gov/2020000333>

6048

Printed in the United States of America

24 23 22 21 20 10 9 8 7 6 5 4 3 2 1

Dedication

To:
The innumerable individuals and communities who are marginalized, we hope this book will give readers a deeper understanding of the importance of inclusivity and health equity;
The indomitable Kitty Ernst, thank you for encouraging us to always look for ways to improve health care; and
Our colleagues, friends, and family members who have been encouraging and patient throughout the labor of this edition. There are too many to mention each of you by name, but you know that we know who you are. We truly appreciate the support you provided.
—*Kerri and Francie*

To:
The many outstanding staff, students, faculty, and administrators at Northern Michigan University and members of NMU's Board of Trustees who provided support for this edition in myriad ways;
Joani, Sue, Lisa, Julia, Judith, Mona, and Jane, whose friendship supports me in ways too many to mention;
Bill, keeper of my heart;
Donovan, for his unconditional love and friendship;
Travis, for keeping me healthy;
My parents, Marie and Don Hall, whose belief that I can do anything makes me believe that I can;
My children, sons-in-law, and grandchildren, Mary, Mike, Spencer, Quinn, Sean, Sarah, Galen, Gryffin, and another grandson soon to arrive, who bring me life's greatest joys; and
Francie, my student who became a highly respected colleague and treasured friend, your expertise in editing is unparalleled. Your significant contributions to our book make each edition better than the last. I sincerely thank you for leading the way with inclusive language that embraces the core philosophy of our book. You are an amazing book partner and I will forever be grateful to have taken this book journey with you.
—*Kerri*

To:
Zan, your love and support for me are unequalled, and I am the luckiest you are mine;
My nephew Knox, my niece Elizabeth, my sister Mary, and my mother Katey, you inspire me in my work to make health care better, and I am very thankful for all of the time and travels we have together;
Ali, you could not be a better friend, and I am so grateful for you, Roberto, Santiago, Bobby, and Luci;
Simon, you and your generous astute advice have helped me become a better writer, editor, and accomplice;
Tekoa, Patty, and Brittany, we are a great team, and working with the three of you has honed the skills I contribute to this book. Tekoa, I am forever appreciative to you for telling me many years ago that I write well and should keep doing that. Your encouragement started me down my path to becoming an author and editor; and
Kerri, the amount and quality of effort you devote to all of your work, including our book, is exceptional. I am grateful we have a collaborative relationship in which valuing our shared attributes, including a relentless attention to detail that anyone else might not find so endearing, and our differing talents and perspectives has strengthened the creation and development of our book. Thank you for being a wonderful book partner and friend.
—*Francie*

CONTENTS

Prefacexiii
Contributors	xv
Reviewersxix
About the Editorsxxi
Section 1 Introduction to Gynecologic Health Care	1
Chapter 1 A Feminist Perspective of Women's Health	3
<i>Lisa Kane Low, Joanne Motino Bailey</i>	
Health Care and Gynecologic Health	3
What Is Feminism?	3
Gender	3
Intersectionality	5
A Model of Care Based on a Feminist Perspective	5
Social Models versus Biomedical Models of Health	6
Feminist Strategies for the Analysis of Health	7
Why a Text on Gynecology?	10
References	10
Chapter 2 Racism and Health Disparities	13
<i>Elizabeth Donnelly, Kim Q. Dau, Karlina Wilson-Mitchell, Jyasha Isis Wren</i>	
Introduction	13
Key Concepts and Definitions	13
History	15
Theories and Related Concepts	19
How Racism Impacts Physiology	24
Inequity in Gynecologic Health	25
Addressing Racism and Race-Associated Disparities	26
Conclusion	32
References	32
Appendix 2-A Additional Resources	37
Chapter 3 Women's Growth and Development across the Life Span	39
<i>Lisa Kane Low, Lee K. Roosevelt</i>	
Adolescence	41
Early Adulthood	46
Midlife	47
Older Women	48
Conclusion	49
References	49
Appendix 3-A Deanow's Model of Development Highlighting Relational Tasks and Obstacles Throughout the Life Span	52

Chapter 4	Using Evidence to Support Quality Clinical Practice	55
	<i>Katherine Camacho Carr, Holly Powell Kennedy, Sascha James-Conterelli, Rachel Blatt</i>	
	What Is Evidence-Based Practice?	55
	A Feminist and Quality Perspective on Research	55
	The History of Evidence-Based Practice	56
	Research and Clinical Decision Making	58
	Types of Research Evidence	59
	Research Methods to Inform Clinical Practice	59
	Moving from Best Evidence to Best Practice	66
	Barriers to Achieving Quality Evidence-Based Practice	66
	Conclusion	67
	References	69
Appendix 4-A	Resources to Improve Quality Care through Evidence-Based Practice	71
Section 2	Health Assessment and Promotion	73
Chapter 5	Health Promotion	75
	<i>Kathryn Osborne</i>	
	Health Promotion: A National Initiative	75
	Defining Health	77
	Defining Prevention	77
	Counseling and Education as Preventive Strategies	78
	Effective Counseling Interventions for Healthy, Asymptomatic Women	78
	Counseling Interventions for Women with Additional Risk Factors	80
	Immunization Guidelines and Recommendations	82
	Conclusion	85
	References	85
Chapter 6	Gynecologic Anatomy and Physiology	87
	<i>Nicole R. Clark</i>	
	Pelvic Anatomy	87
	Female Genitalia	90
	Breast Anatomy and Physiology	93
	Menstrual Cycle Physiology	94
	Considerations	97
	References	98
Chapter 7	Gynecologic History and Physical Examination	99
	<i>Stephanie Tillman, Frances E. Likis</i>	
	Context and Approach: Trauma-Informed Care	99
	Health History	100
	Physical Examination for a Gynecologic Visit	108
	Conclusion: Summing Up and Documenting Findings	123
	References	124
Appendix 7-A	Cervical Cytology Screening	125
Appendix 7-B	Screening for <i>Chlamydia trachomatis</i> , <i>Neisseria gonorrhoeae</i> , and <i>Trichomonas vaginalis</i> Infections	128
Appendix 7-C	Preparing a Sample of Vaginal Secretions for Microscopic Examination	130
Appendix 7-D	Anal Cytology Screening	131
Chapter 8	Male Sexual and Reproductive Health	133
	<i>Hanne S. Harbison</i>	
	Introduction	133
	Reproductive Anatomy	133
	Reproductive Physiology	135
	Sexual and Reproductive Health Assessment	135
	Sexually Transmitted Infections	138
	Male Sexual Dysfunction	141
	Contraception	143
	Testicular Cancer	144

Gay and Bisexual Men's Health	144
References	146
Chapter 9 Periodic Screening and Health Maintenance	149
<i>Kathryn Osborne</i>	
Health Maintenance: A National Priority	149
Grade A and B Screening Recommendations for All Women	151
Grade A and B Screening Recommendations for Older Women	156
Special Populations	159
Additional Observations	162
References	162
Chapter 10 Women's Health after Bariatric Surgery	165
<i>Theresa M. Durley, Anne Stein</i>	
Introduction	165
Description	165
Assessment	166
Prevention	167
Management	167
Patient Education	168
Considerations for Specific Populations	168
Conclusion	171
References	171
Chapter 11 Gynecologic Health Care for Lesbian, Bisexual, and Queer Women and Transgender and Nonbinary Individuals	173
<i>Simon Adriane Ellis</i>	
Gender and Sexuality Concepts	173
Social and Political Context	176
Culturally Responsive Care	178
Social Determinants of Health Affecting Lesbian, Bisexual, and Queer Women	180
Barriers to Health Care for Lesbian, Bisexual, and Queer Women	182
Health Disparities among Lesbian, Bisexual, and Queer Women	183
Social Determinants of Health Affecting Transgender and Nonbinary Individuals	187
Barriers to Health Care for Transgender and Nonbinary Individuals	188
Gender-Affirming Care for Transgender and Nonbinary Individuals	190
Health Disparities among Transgender and Nonbinary Individuals	193
Considerations for Specific Populations	199
Conclusion	201
References	201
Chapter 12 Sexuality and Sexual Health	211
<i>Phyllis Patricia Cason</i>	
Definitions of Key Terms	211
Sexual Practices and Behaviors	212
Sexual Desire	214
Sexual Self-Knowledge	215
Sexual Agency	218
Control over Pelvic Muscles	219
Products to Enhance Sexual Health	220
Assessment of Sexual Health	222
Considerations for Specific Populations	224
Conclusion	228
References	228
Appendix 12-A Sexuality Resources for Patients and Providers	233
Chapter 13 Contraception	235
<i>Rachel Newhouse</i>	
Contraceptive Efficacy and Effectiveness	236
Long-Acting Reversible Contraception	238
Permanent Contraception	242

	Hormonal Methods	243
	Emergency Contraception	251
	Nonhormonal Methods	252
	References	259
Appendix 13-A	Recommended Resources	264
Appendix 13-B	Primary Mechanisms of Action of Contraceptive Methods	265
Chapter 14	Menopause	267
	<i>Ivy M. Alexander, Annette Jakubisin Konicka, Zahra A. Barandouzi, Christine Alexandra Bottone, Elizabeth Mayerson, Matthew Witkovic</i>	
	The Medicalization of Menopause: A Historical Perspective	267
	Natural Menopause	268
	Menopause from Other Causes	270
	Diagnosing Menopause	271
	Presentation and Variation of the Menopause Experience	272
	Midlife Health Issues	273
	Patient Education for Lifestyle Approaches to Manage Menopause-Related Symptoms	278
	Pharmacologic Options for Menopause-Related Symptom Management	281
	Complementary and Alternative Medicine Options for Menopause-Related Symptom Management	287
	Conclusion	291
	References	291
Chapter 15	Intimate Partner Violence	295
	<i>Christina M. Boyland, Kelly A. Berishaj</i>	
	Definitions	295
	Types of Intimate Partner Violence	295
	Theories of Intimate Partner Violence	296
	Epidemiology	297
	Risk Factors	297
	Intimate Partner Violence-Related Impacts	297
	Clinical Presentation	297
	Evaluation of the Patient Experiencing IPV	299
	Blunt Force Injuries	302
	Sharp Force Injuries	302
	Documentation	303
	Management	303
	Strangulation	304
	Considerations for Specific Populations	305
	Preventing Intimate Partner Violence	307
	References	307
Appendix 15-A	The Four Phases in the Cycle of Abuse	310
Appendix 15-B	HITS (Hurt-Insult-Threaten-Scream) Domestic Violence Screening Tool	311
Chapter 16	Sexual Assault	313
	<i>Kelly A. Berishaj</i>	
	Definitions	313
	Epidemiology	313
	Clinical Presentation and Concerns Following Sexual Assault	314
	Evaluation of the Sexual Assault Patient	318
	Management	324
	Medical Follow-Up	326
	Considerations for Specific Populations	326
	Prevention	328
	Conclusion	328
	References	329
Appendix 16-A	Clinician Resources	331
Appendix 16-B	Signs and Symptoms of Strangulation	332
Appendix 16-C	Body Diagram	333

Section 3	Gynecologic Healthcare Management	335
Chapter 17	Breast Conditions	337
	<i>Kathryn J. Trotter</i>	
	Mastalgia	337
	Nipple Discharge	340
	Benign Breast Masses	341
	Breast Cancer	343
	References	349
Appendix 17-A	Online Resources	352
Chapter 18	Alterations in Sexual Function	353
	<i>Brooke M. Faught</i>	
	Models of Sexual Response	353
	Definitions of Female Sexual Dysfunction	354
	Scope of the Problem	354
	Etiology	354
	General Assessment for Sexual Concerns	355
	Further Assessment and Management of Specific Types of Sexual Dysfunction	357
	Referral to Therapists Specializing in Sexual Dysfunction	363
	References	364
Chapter 19	Pregnancy Diagnosis, Decision-Making Support, and Resolution	367
	<i>Katherine Simmonds, Frances E. Likis, Julia C. Phillippi</i>	
	Clinically and Ethically Competent Care in the Pregnancy Discovery, Decision-Making, and Resolution Process	367
	Assessment	369
	Pregnancy Options Counseling	369
	Options for Resolving Pregnancy	371
	Considerations for Specific Populations	377
	Pregnancy Intention	378
	References	379
Chapter 20	Infertility	383
	<i>Monica Moore</i>	
	Scope of the Condition	383
	Reproductive Anatomy and Physiology Related to Infertility	384
	Etiologies of Infertility	385
	Assessment of Infertility	386
	Differential Diagnosis	392
	Prevention of Infertility	392
	Management of Infertility	392
	Other Options for Individuals with Infertility	396
	Evidence for Best Practices Related to Infertility Care	396
	Additional Considerations	396
	References	398
Chapter 21	Gynecologic Infections	401
	<i>Sharon M. Bond</i>	
	Promoting and Maintaining Vaginal Health	401
	The Vaginal Microbiome	401
	Vaginitis, Vaginosis, and Vulvovaginitis	403
	Bacterial Vaginosis	403
	Vulvovaginal Candidiasis	412
	Desquamative Inflammatory Vaginitis	417
	Atrophic Vaginitis and GSM	419
	Toxic Shock Syndrome	425
	Bartholin Duct Cysts and Abscesses	427
	Genital Piercing	429
	References	432

Chapter 22 Sexually Transmitted Infections	437
<i>Heidi Collins Fantasia</i>	
Introduction	437
Transmission of Sexually Transmitted Infections	437
Sexually Transmitted Infection Screening and Detection	440
Assessment	440
Education and Prevention	441
Reporting	442
Considerations for Specific Populations	443
Human Papillomavirus and Genital Warts	444
Genital Herpes	446
Chancroid	450
Pediculosis Pubis	451
Trichomoniasis	451
Chlamydia	453
Gonorrhea	454
Pelvic Inflammatory Disease	455
Syphilis	458
Hepatitis B	461
Hepatitis C	462
HIV	463
Conclusion	466
References	466
Chapter 23 Urinary Tract Infections	469
<i>Mickey Gillmor-Kahn</i>	
Scope of the Problem	469
Etiology	469
Types of Urinary Tract Infections	469
Assessment	471
Differential Diagnoses	472
Management	472
Considerations for Specific Populations	475
References	475
Chapter 24 Urinary Incontinence	479
<i>Ying Sheng, Janis M. Miller</i>	
Introduction	479
Scope of the Problem	479
Assessment	482
Differential Diagnoses	485
Prevention	485
Management	486
Patient Education	490
Considerations for Specific Populations	490
Internet Resources	491
References	492
Chapter 25 Menstrual Cycle Pain and Premenstrual Syndrome	495
<i>Ruth E. Zielinski, Sarah Maguire, Kerri Durnell Schuling</i>	
Overview	495
Dysmenorrhea	495
Etiology and Pathophysiology	496
Premenstrual Cycle Syndromes and Dysphoric Disorder:	
An Overview	499
Conclusion	507
References	507

Chapter 26	Normal and Abnormal Uterine Bleeding	511
	<i>Ruth E. Zielinski, Lee K. Roosevelt</i>	
	Introduction	511
	Normal Uterine Bleeding	511
	AUB Nomenclature	513
	Subjective Information: The Evaluation	513
	The Objective Evaluation	514
	Differential Diagnosis of AUB	517
	Management Plans	520
	Management of Amenorrhea	524
	Considerations for Specific Populations	525
	Conclusion	526
	References	526
Appendix 26-A	Instructions for Performing an Endometrial Biopsy	528
Chapter 27	Hyperandrogenic Disorders	529
	<i>Maureen Shannon</i>	
	Description of Hyperandrogenic Disorders	529
	Clinical Presentation	530
	Assessment	533
	Making the Diagnosis of Polycystic Ovary Syndrome	535
	Differential Diagnoses	535
	Prevention	535
	Management	535
	Considerations for Specific Populations	539
	References	540
Chapter 28	Benign Gynecologic Conditions	543
	<i>Eva M. Fried</i>	
	Conditions of the Vulva	543
	Conditions of the Uterus and Cervix	553
	Conditions of the Adnexa	563
	References	566
Chapter 29	Gynecologic Cancers	569
	<i>Nancy A. Maas, Kristi Adair Robinia</i>	
	Vulvar Cancers	569
	Cervical Cancer	575
	Endometrial Cancer	583
	Ovarian Cancer	589
	References	597
Chapter 30	Chronic Pelvic Pain	601
	<i>Melissa Romero</i>	
	Introduction	601
	Description and Definition	601
	Assessment	603
	Differential Diagnoses	606
	Gastrointestinal Causes of Pelvic Pain	610
	Management	611
	When to Refer	613
	Current and Emergent Evidence for Practice	613
	Patient Education	614
	Considerations for Specific Populations	614
	References	616
Appendix 30-A	The International Pelvic Pain Society Pelvic Pain Assessment Form	618
Appendix 30-B	The Institute for Women in Pain Initial Female Pelvic Pain Questionnaire	629
Appendix 30-C	The International Pelvic Pain Society Chronic Pelvic Pain Patient Education Booklet	646

Section 4 Introduction to Prenatal and Postpartum Care	653
Chapter 31 Preconception Care	655
<i>Kathleen Danhausen, Amy Romano</i>	
Introduction	655
The Approach to a Person Hoping to Become Pregnant in the Next Year	656
Assessment and Counseling Related to Lifestyle and Behavioral Factors	657
Assessment of Genetic Risk	662
Assessment of Preventive Health Practices	662
Assessment and Management of Infection Risk	665
Assessment of Health Conditions and Medications That May Impact Fertility or Pregnancy	665
Assessment and Counseling Related to Perinatal History	670
Conclusion	672
References	673
Chapter 32 Anatomic and Physiologic Adaptations of Normal Pregnancy	677
<i>Ellise D. Adams</i>	
Introduction	677
Breast Changes	677
Reproductive System Changes	677
Integumentary System Changes	679
Gastrointestinal Changes	679
Cardiovascular System and Hematologic Changes	679
Respiratory System Changes	680
Renal System Changes	680
Musculoskeletal System Changes	681
Endocrine System Changes	681
Neurologic System and Psychosocial Changes	681
Conclusion	681
References	681
Chapter 33 Overview of Prenatal Care	683
<i>Julia C. Phillippi, Bethany Sanders</i>	
Introduction	683
Diagnosis of Pregnancy	683
Assessment	683
Management	689
First-Trimester Bleeding	692
Planning for Pregnancy Care	693
References	694
Chapter 34 Common Complications of Pregnancy	697
<i>Ellise D. Adams, Kerri Durnell Schulling</i>	
Infections Commonly Diagnosed during Pregnancy	697
First-Trimester Complications	702
Second-Trimester Complications	705
Third-Trimester Complications	708
Conclusion	710
References	710
Chapter 35 Overview of Postpartum Care	713
<i>Deborah Brandt Karsnitz, Kelly Wilhite</i>	
Postpartum Physiology	713
Postpartum Care	715
Postpartum Assessment	715
Postpartum Examinations	716
Breastfeeding Complications	723
Selected Postpartum Complications	724
Conclusion	730
References	730
Index	733

PREFACE

Historically, gynecologic health was framed within a biomedical model by clinicians. A biomedical model is disease oriented and focuses on curing illness—an approach that risks pathologizing normal aspects of physiology. When a biomedical lens is used to assess people’s health, there is a risk of essentializing individuals and reducing them to their biologic parts. This reductionism transfers to practice when an individual’s body parts become the focus of diagnosis and treatment. The meaning of the diagnosis to the individual, and the impact that the diagnosis has on them, their significant others, and their life, is not addressed in this approach.

In contrast to the biomedical model, a holistic model assesses health within the context of each individual’s life. A holistic approach is grounded in caring for the whole person within their lived experience. Each person is recognized as an expert knower whose agency should be supported. As experienced clinicians, we use this holistic practice philosophy as an overarching framework for this text. A related core principle of the text is our use of the health-oriented perspective that is vital to the philosophy of care espoused by nursing and midwifery, in which we both strongly believe.

We initially embarked on creating a book that presented gynecologic health from a woman-centered, holistic, and feminist viewpoint. Our goal was to produce a book that emphasized the importance of respecting normal physiology; provided evidence-based clinical content appropriate for assessment, diagnosis, and treatment; and promoted the value of collaboration among clinicians. Some aspects of this holistic, feminist approach will be obvious to readers, whereas others may be more subtle. For example, we use illustrations of whole individuals, rather than pictures of only breasts or genitalia, when possible. We refer to a person who has a specific condition rather than referring to the person by their condition. For example, we speak of the individual who has HIV, as opposed to the HIV-positive individual. We use the term “birth” as opposed to “delivery” because it situates the power within the person giving birth versus transferring it to the clinician. And for the first three editions of this text, we purposefully used “women’s” rather than “gynecologic” as the first word of the book’s title. Our intention in making these deliberate choices was to encourage readers to keep first in their mind that they are treating a whole person, not just body parts or a condition. We hope that this approach emphasizes the importance of treating all individuals holistically within their lived experiences.

As we began work on the fourth edition of this text, we recognized the need for our book to better support gender-inclusive health care. Transgender and nonbinary people deserve compassionate clinicians who understand their unique healthcare needs. One of our goals for this edition is to maintain the core philosophical beliefs from the previous editions while broadening them to incorporate gender inclusiveness. A gender-inclusive approach is consistent with the book’s person-centered, holistic, feminist foundation. Although this edition does not remove all gendered language, we address the need for gender-inclusive care throughout the text and changed the title to the gender-inclusive *Gynecologic Health Care*. Our decision to keep some gendered language, which is discussed later, is not meant to exclude people who do not identify as women and seek gynecologic care or become pregnant.

The shift in gender language in this new edition has been challenging. It can be difficult to balance the desire to be gender inclusive and holistic with the need to provide clear information and accurate presentation of original sources. The language of health care and previous editions of this book is gendered. Historically, health care and health-related research have been based on a gender binary in which there are only two genders, female and male, and gender is determined by sex assigned at birth. While it is now recognized that gender is not binary and does not always align with sex assigned at birth, one cannot ignore the long-standing use of a gender binary. For example, most studies to date report the gender of participants based on their sex assigned at birth. Changing the original language of a source, such as using only gender-neutral language for a study reported to have “women” as its participants, does not accurately portray the information that was published. In addition, it is impossible to simply change every gendered word to gender-neutral alternatives, such as “individual” or “they,” because everyone does not have the same anatomy. The sex individuals are assigned at birth affects their health. For example, the assessment and management of sexually transmitted infections differs depending on whether one has a vagina or a penis, so it can become confusing to use only gender-neutral language when discussing this topic. As an alternative to gendered language, some have proposed language such as “people with vaginas.” However, identifying people by their genitals is counter to our strongly held principle of avoiding reductionism. Last, but certainly not least, the prominent use of the word “women” in the first three editions of this text was very intentional, and we struggled with where to retain and remove it. We do not want to reverse the great progress that has been made in positioning women, not just their body parts or conditions, as the focus of their health care. We also do not want to lose sight of how sexism profoundly affects women’s lives, including their health.

This edition was written at a time when gender language was rapidly evolving and still the source of controversy. Being at the forefront of this evolution with a textbook is risky. Some readers will like the gender inclusivity in this edition, and others will not. Some will think we have moved too far toward inclusivity, and others will think we have not moved far enough. In a few years, it

Elizabeth Donnelly, CNM, WHNP-BC

Midwife
Kaiser Permanente
Walnut Creek, California

Theresa M. Durley, DNP, MPA, CRNA, FNP-C

Assistant Professor
School of Nursing
Northern Michigan University
Marquette, Michigan

Simon Adriane Ellis, MSN, CNM

Nurse-Midwife
Kaiser Permanente
Seattle, Washington

Heidi Collins Fantasia, PhD, RN, WHNP-BC

Associate Professor
Zuckerberg College of Health Sciences, Susan and Alan
Solomont School of Nursing
University of Massachusetts
Lowell, Massachusetts

Brooke M. Faught, DNP, WHNP-BC, NCMP, IF

Director
Women's Institute for Sexual Health (WISH)
Adjunct Faculty
Vanderbilt University School of Nursing
Nashville, Tennessee

Eva M. Fried, DNP, CNM, WHNP

Nurse-Midwifery Program Director
University of Cincinnati
Cincinnati, Ohio

Mickey Gillmor-Kahn, MN, CNM

Course Faculty
Frontier Nursing University
Versailles, Kentucky

Hanne S. Harbison, MHSPH, MSN, WHNP-BC

Associate Director, Women's Health Gender-Related Nurse
Practitioner Track
University of Pennsylvania
School of Nursing
Philadelphia, Pennsylvania

**Annette Jakubisin Konicki, PhD, ANP-BC, FNP-BC,
FAANP**

Associate Professor
Director
Family Nurse Practitioner Primary Care Track
University of Connecticut
School of Nursing
Storrs, Connecticut

Sascha James-Conterelli, DNP, CNM, FACNM

Faculty-Lecturer in Nursing
Nurse-Midwife
Yale School of Nursing
Orange, Connecticut

Deborah Brandt Karsnitz, DNP, CNM, FACNM

Interim DNP Program Director
Professor
Frontier Nursing University
Versailles, Kentucky

Holly Powell Kennedy, PhD, CNM, FACNM, FAAN

Varney Professor of Midwifery
Yale School of Nursing
Orange, Connecticut

Lisa Kane Low, PhD, CNM, FACNM, FAAN

Professor
Associate Dean Practice and Professional Graduate Studies
Professor, Nursing, Women's Studies, and Obstetrics and
Gynecology
University of Michigan
Ann Arbor, Michigan

Nancy A. Maas, MSN, FNP-BC, CNE

Professor
Northern Michigan University
School of Nursing
Marquette, Michigan

Sarah Maguire, BS, BSN, NP-C, CNM

Maternal & Fetal Medicine NP
Certified Nurse-Midwife
Birth Center
Michigan Medicine
Ann Arbor, Michigan

Elizabeth Mayerson, DNP, RN, APRN, FNP-BC

Assistant Clinical Professor
University of Connecticut
Storrs, Connecticut

Janis M. Miller, PhD, ANP, FAAN

Professor
School of Nursing
University of Michigan
Ann Arbor, Michigan

Monica Moore, MSN, RNC

Founder and Lead Educator
Fertile Health, LLC
Ponte Vedra Beach, Florida

Rachel Newhouse, PhD, CNM

College of Nursing
University of Illinois at Chicago
Chicago, Illinois

Kathryn Osborne, RN, CNM, PhD

Associate Professor
Department of Women, Children and Family Nursing
College of Nursing
Rush University
Chicago, Illinois

Julia C. Phillippi, PhD, CNM, FACNM, FAAN

Assistant Professor
Nurse-Midwifery Specialty Director
School of Nursing
Vanderbilt University
Nashville, Tennessee

Kristi Adair Robinia, PhD, RN

Associate Dean and Director
School of Nursing
Northern Michigan University
Marquette, Michigan

Amy Romano, MSN, CNM, MBA

Independent Consultant
Milford, Connecticut

Melissa Romero, PhD, FNP-BC

Professor and Graduate Program Coordinator
School of Nursing
Northern Michigan University
Marquette, Michigan

Lee K. Roosevelt, PhD, MPH, CNM

Clinical Assistant Professor
University of Michigan
School of Nursing
Ann Arbor, Michigan

Bethany Sanders, CNM, MSN

Instructor of Clinical Nursing
Vanderbilt University School of Nursing
Faculty Attending Nurse-Midwife
Vanderbilt University Medical Center
Nashville, Tennessee

Maureen Shannon, PhD, CNM, FAAN, FACNM

Associate Dean for Academic Programs
School of Nursing
University of California
San Francisco, California

Ying Sheng, PhD, RN

Postdoctoral Research Fellow
Indiana University
School of Nursing
Indianapolis, Indiana

Katherine Simmonds, PhD, MPH, RN, WHNP-BC

Assistant Professor and Coordinator Women's Health/Gender-related NP Track
School of Nursing
MGH Institute of Health Professions
Charlestown, Massachusetts

Anne Stein, PhD, FNP-BC, COHN-S

Associate Professor
School of Nursing
Northern Michigan University
Marquette, Michigan

Stephanie Tillman, CNM, MSN

Nurse-Midwife
Clinical Instructor
University of Illinois at Chicago
Chicago, Illinois

Kathryn J. Trotter, DNP, CNM, FNP-C, FAANP, FAAN

Associate Professor
Lead Faculty, Women's Health NP Major
School of Nursing
Duke University
Durham, North Carolina

Kelly Wilhite, DNP, APRN, CNM

Assistant Professor
Frontier Nursing University
Versailles, Kentucky

Karline Wilson-Mitchell, DNP, MSN, CNM, RM, RN, FACNM

Associate Professor
Midwifery Education Program
Ryerson University
Toronto, Canada

Matthew Witkovic, DNP, FNP-BC

Adjunct Clinical Faculty
University of Connecticut
Storrs, Connecticut

Jyesha Isis Wren, MS, CNM

Alameda Health System
Alameda County, California

Ruth E. Zielinski, PhD, CNM, FACNM, FAAN

Clinical Professor
Program Lead UM Midwifery Program
University of Michigan School of Nursing
Chair-ACNM Clinical Practice & Documents Section
Ann Arbor, Michigan

REVIEWERS

Amy Alspaugh, PhD, MSN, CNM

Postdoctoral Fellow
University of California San Francisco
San Francisco, California

Megan W. Arbour, PhD, CNM, CNE, FACNM

Associate Professor
Frontier Nursing University
Versailles, Kentucky

Lindsey A. Baksh, DNP, WHNP-BC

Assistant Professor, Clinical Obstetrics and Gynecology
Vanderbilt University Medical Center
Instructor of Nursing
Vanderbilt University School of Nursing
Nashville, Tennessee

Patricia W. Caudle, DNSc, FNP-BC (ret.), CNM

Associate Professor (retired)
Frontier Nursing University
Versailles, Kentucky

Ali S. Cocco, MDiv, MSN, CNM

Instructor, Clinical Obstetrics and Gynecology
Vanderbilt University
Nashville, Tennessee

Rena M. Diegel, RN, BBL, SANE-A

Administrator of Clinical Forensic Nursing Services
Turning Point's Regional Forensic Nurse Examiner Program
Clinton Township, Michigan

Dawn Durain, CNM, MPH, FACNM

Senior Lecturer
University of Pennsylvania
Philadelphia, Pennsylvania

Meghan Eagen-Torkko, PhD, CNM, ARNP

Assistant Professor
University of Washington Bothell
Bothell, Washington
Clinician
Family Planning Program
Public Health Seattle-King County
Seattle, Washington

Mary Ellen Egger, BSN, MSN, WHNP-BC

Nurse Practitioner
Vanderbilt Breast Center
Nashville, Tennessee

Mary R. Franklin, DNP, CNM

Director, Nurse-Midwifery Program
Frances Payne Bolton School of Nursing
Case Western Reserve University
Cleveland, Ohio

Deana Hays, DNP, FNP-BC

Assistant Professor
Oakland University School of Nursing
Nurse Practitioner Beaumont Health System
Rochester, Michigan

Caroline M. Hewitt, DNS, WHNP-BC, ANP-BC

Director of Advanced Practice
Atrius Health
Boston, Massachusetts

Aimee Chism Holland, DNP, WHNP-BC, FNP-C, FAANP

Associate Professor
University of Alabama at Birmingham School of Nursing
Birmingham, Alabama

Amy Hull, MSN, WHNP-BC

Assistant Professor
Department of Obstetrics and Gynecology
Vanderbilt University Medical Center
Nashville, Tennessee

Elizabeth Kusturiss, MSN, CRNP, IF

Nurse Practitioner
Virtua Sexual Wellness & Pelvic Health
Voorhees, New Jersey

Miriam E. Levi, CNM, FNP-BC, WHNP-BC, IBCLC

Medical Director
Just Living Healthcare
Anacortes, Washington

Denise M. Linton, DNS, APRN, FNP-BC

Associate Professor
University of Louisiana at Lafayette
Lafayette, Louisiana

Lisa Kane Low, PhD, CNM, FACNM, FAAN

Professor, Nursing, Women's Studies, and Medicine
University of Michigan
Ann Arbor, Michigan

Laura Manns-James, PhD, CNM, WHNP-BC, CNE

Associate Professor
Frontier Nursing University
Versailles, Kentucky

Hayley D. Mark, PhD, RN, FAAN

Professor and Chair
Towson University
Towson, Maryland

Alison O. Marshall, RN, MSN, FNP-BC

Clinical Instructor
Boston College Connell School of Nursing
Chestnut Hill, Massachusetts

Latrice Martin, DNP, CNM, FNP-C, IBCLC

Course Faculty and Regional Clinical Faculty
Frontier Nursing University
Versailles, Kentucky

Ginny Moore, DNP, WHNP-BC

Associate Professor
Women's Health Nurse Practitioner Academic Director
Vanderbilt University School of Nursing
Nashville, Tennessee

Aiden Nicholson, APN, CNM, AAHIVS

Certified Nurse-Midwife
Howard Brown Health
Chicago, Illinois

Tonya Nicholson, DNP, CNM, WHNP-BC, CNE, FACNM

Associate Dean of Midwifery and Women's Health
Associate Professor
Frontier Nursing University
Versailles, Kentucky

Rachel Nye, DNP, MS, FNP-BC, RNC-OB, C-EFM, CNE

Professor
Northern Michigan University
Marquette, Michigan

Signey Olson, CNM, WHNP-BC

Nurse Practitioner, Nurse-Midwife
Columbia Fertility Associates
Adjunct Instructor
Georgetown University
Washington, District of Columbia

Alisa A. Pascale, DNP, WHNP-BC

Clinical Faculty
MGH Institute of Health Professions
Boston, Massachusetts

Robinson Reed, CNM, ARNP, IBCLC

Certified Nurse Midwife
Swedish Medical Center—First Hill
Seattle, Washington

Pamela Reis, PhD, CNM, NNP-BC, FACNM

Associate Professor
East Carolina University
Greenville, North Carolina

Tammy J. Senn, MSN, CNM, WHNP-BC, CSC

Certified Nurse-Midwife
Department of Gynecology
Johns Hopkins Hospital
Baltimore, Maryland

Katherine Levy Sibling, BSN, MSN, WHNP-BC

Nurse Practitioner
Vanderbilt Breast Center
Nashville, Tennessee

Joan Slager, DNP, CNM, FACNM

Dean of Nursing
Frontier Nursing University
Versailles, Kentucky

Mary Alison Smania, DNP, FNP-BC, AGN-BC, FAANP

Assistant Professor
Michigan State University
East Lansing, Michigan

Ana Verzone, DNP, APRN, FNP-BC, CNM

Course faculty
Frontier Nursing University
Versailles, Kentucky

Katherine Ward, DNP, WHNP

Associate Professor, Clinical
Specialty Director, Women's Health Nurse Practitioner Program
University of Utah College of Nursing
Salt Lake City, Utah

Penny Wortman, DNP, CNM

Assistant Professor
Frontier Nursing University
Versailles, Kentucky

ABOUT THE EDITORS

Kerri Durnell Schuiling, PhD, NP, CNM, FACNM, FAAN, earned her bachelor's degree from Northern Michigan University, her master's degree in advanced maternity nursing from Wayne State University, and a PhD in nursing and a graduate certificate in women's studies from the University of Michigan. She received her nurse practitioner education from Planned Parenthood Association of Milwaukee, Wisconsin, and her nurse-midwifery education from Frontier Nursing University. She is a certified nurse-midwife and a women's healthcare nurse practitioner, and she has been an advanced practice registered nurse and educator for more than 40 years. She has presented numerous times to national and international audiences on topics that focus on women's health, and twice she was invited to provide formal presentations to maternal child health committees of the Institute of Medicine. As a member of the American College of Nurse-Midwives (ACNM) Clinical Practice Committee, Kerri assisted in the development of ACNM clinical bulletins related to abnormal uterine bleeding and has been an item writer for the National Certification Examination for women's healthcare nurse practitioners. Kerri has authored numerous articles and book chapters that focus on women's health. She has received numerous awards for her work, including a Clinical Merit Award from the University of Michigan for outstanding clinical practice; the Kitty Ernst award from the ACNM in recognition of innovative, creative endeavors in midwifery and women's health care; the Esteemed Women of Michigan award from the Burnstein Clinic for her significant contributions to women's health, the Distinguished Service to Society Award from Frontier Nursing University, and, most recently, the Crain's Award for Michigan's Notable Women in Educational Leadership. She is a Fellow of the ACNM and the American Academy of Nursing. Currently she is a distinguished professor and Provost and Vice President of Academic Affairs at Northern Michigan University. She is the founding Co-Editor-in-Chief of the *International Journal of Childbirth*.

Frances E. Likis, DrPH, NP, CNM, FACNM, FAAN, earned her bachelor's and master's degrees from Vanderbilt University and her doctorate in public health from the University of North Carolina at Chapel Hill. She received her nurse-midwifery education from Frontier Nursing University and earned a certificate in medical writing and editing from the University of Chicago. She is a women's healthcare nurse practitioner, family nurse practitioner, and certified nurse-midwife, and she has been an advanced practice registered nurse for more than 25 years. Francie is nationally recognized for advancing evidence-based best practice in women's health and bringing gynecologic and reproductive health further into mainstream nursing and midwifery practice. She was the only nurse on the Vanderbilt University Evidence-based Practice Center faculty and led interprofessional teams conducting systematic reviews examining critical questions in health care. Under her leadership, the *Journal of Midwifery & Women's Health* has increased to its highest impact factor ever, and the number of submissions continues to rise annually. She has been an educator and mentor for graduate students throughout her career, initially as a clinical preceptor and later as a faculty member at Vanderbilt University and Frontier Nursing University. She has authored numerous journal articles, systematic reviews, and book chapters, and she has given presentations and invited lectures at a variety of national meetings and institutions. Francie's awards and honors include the ACNM Kitty Ernst Award, the Vanderbilt University Alumni Award for Excellence in Nursing, the Frontier Nursing University Distinguished Service to Society Alumni Award, and the Frontier Nursing University Student Choice Award for Teaching Excellence. She is a Fellow of the ACNM and the American Academy of Nursing. Currently she is the Editor-in-Chief of the *Journal of Midwifery & Women's Health*, the official journal of the ACNM, and an Adjunct Assistant Professor of Nursing at Vanderbilt University.

Introduction to Gynecologic Health Care

CHAPTER 1

A Feminist Perspective of Women's Health

CHAPTER 2

Racism and Health Disparities

CHAPTER 3

Women's Growth and Development across the Life Span

CHAPTER 4

Using Evidence to Support Quality Clinical Practice

A Feminist Perspective of Women's Health

Lisa Renee Cox

Jocelyn Hopkins Bailey

HEALTH CARE AND GYNECOLOGIC HEALTH

The state of health care today reflects the intersections of the varied identities we hold combined with our position in society. Many healthcare advances have been made, yet comprehensive, compassionate healthcare services that address the complexity and diversity of how we live our lives and experience health and disease are still lagging.

This text is based on a feminist framework in an effort to advance the quality of health care generally; it was initially aimed at addressing disparities in women's health care in today's society. The complexity of women's health is considered by paying attention to women's status in society and their unequal access to opportunity and power, while focusing on women's gynecologic health and well-being. When we say "women," do we really mean all women? Transgender women, transgender men, and nonbinary-identifying individuals may find that the terms "woman" and "women's health" are exclusionary, creating a silence or invisibility to their lived experience of health and health care. Language remains imperfect as we continue to search for inclusive ways to describe varied experiences regarding health, particularly gynecologic health. Throughout this chapter we have retained the terms "woman" and "women's health" and acknowledge that this does present complexities and challenges in addressing health disparities and being inclusionary. We address this challenge by using nongendered language when possible and by retaining the word "woman" when it is essential to the context and example being presented.

The purpose of this chapter is to provide an overview of the experience of health using a feminist perspective and gender considerations as a lens for exploring women's health in general and gynecologic health in particular. The glossary in **Box 1-1** offers definitions of key terms that are used throughout this text and are linked to feminist critical analysis of gender and health.

WHAT IS FEMINISM?

The author bell hooks (2000) offers a definition of feminism that is well suited for addressing the context in which people experience health and wellness: feminism is a perspective that acknowledges the oppression of women within a patriarchal society and struggles toward the elimination of sexist oppression and domination for all human beings. Acknowledging the oppression of

women is increasingly difficult because affluence and increased opportunities within some sectors of employment and education are construed as equal access or equity in opportunity. However, hooks defines oppression as "not having a choice." With this definition, many more individuals can recognize constraints in their personal experiences. Examples of such practices include unjust labor practices, lower wages for equal work, lack of maternity leave policies, limited access to a range of contraceptive options, and inability to access desired healthcare providers. These examples indicate the breadth of experiences within the context of a patriarchal society that denies women equal access to power, resources, and opportunities.

Characteristics of a feminist perspective include the use of critical analysis to question assumptions about societal expectations and the value of various roles on both sociopolitical and individual levels. The process of critical analysis is accomplished by rejecting conceptualizations of women as homogeneous and acknowledging the range of experiences and expressions of sex/gender. It acknowledges power imbalances and uses the influence of gender as the foremost consideration in the analysis. Using a gender lens that is informed by feminism permits areas of disparity to be identified both among groups, based on gender, and within groups, based on the recognition of heterogeneity.

Feminist health perspective explores the context of how individuals generally, and women specifically, live their lives both collectively and individually within a patriarchal society. The various social, environmental, and economic aspects become integral to understanding the context in which people are able to achieve health and well-being. Furthermore, feminism requires consideration of health, as influenced by the intersection of sexism, racism, class, nation, and gender, within a framework that acknowledges the role of oppression as it affects women and their health as individuals and as a group. **Box 1-2** summarizes the components of a feminist perspective when considering health issues or models of care, which can help reframe one's view of the experience of health from a feminist perspective.

GENDER

What does gender have to do with the experience of health? Although women's health is focused on the female sex (as determined by chromosomes, genitalia, and sexual organs), its priorities are shaped by what are considered socially important

BOX 1-1 Glossary of Key Terms

- cisgender:** An individual whose gender identity coincides with that individual's birth-assigned sex (e.g., a cisgender man is often referred to as simply "man," and a cisgender woman is often referred to as simply "woman").
- classism:** Discrimination or prejudice on the basis of social class.
- discrimination:** The prejudicial treatment of an individual based on that person's actual or perceived membership in a certain group or category (e.g., race, ethnicity, sexual orientation, national origin).
- feminism:** A movement to end sexism, sexist exploitation, and oppression (hooks, 2000).
- gender:** A socially constructed category addressing how people identify and act based on sex (e.g., men and women).
- homophobia:** Prejudice against individuals with same-sex attraction.
- intersectionality:** The unique combination of multiple identities based on race, class, gender, and other characteristics, and the compounded experience of oppression based on these identities.
- medicalization:** Defining or treating a physiologic process or behavior as a medical condition or disease.
- oppression:** Exercise of authority or power in an unjust manner; according to hooks (2000), "not having a choice."
- patriarchy:** A social system of institutions that privileges men, resulting in male domination over access to power, roles, and positions within society.
- power:** The ability to do something, act in a particular way, or direct/influence others' behavior or a course of events.
- race/ethnicity:** Socially constructed categorization of individuals and communities based on a combination of physical attributes and cultural heritage.
- racism:** Individual and structural practices that create and reinforce oppressive systems of race relations.
- sex:** Biological classification as female or male based on chromosomes, genitalia, and reproductive organs.
- sex/gender:** Combined term of sex and gender acknowledging that the discreet meanings of these terms are not easily separated in research and practice.
- sexism:** Individual and institutional practices that privilege men over women.
- social construction:** The process by which societal expectations of behavior become interpreted as innate, biologically determined characteristics.
- socioeconomic status:** An indicator that encompasses income, education, and occupation.
- structural racism:** Macro-level systems, social forces, institutions, and processes that reinforce oppressive race relations.
- trans*:** A term, pronounced "trans star," that represents multiple identities in transgender communities (Erickson-Schroth, 2014).
- transgender or trans:** An individual whose gender identity does not coincide with that individual's assigned sex at birth.

BOX 1-2 Components of a Feminist Perspective in Health

- Works *with* individuals as opposed to *for* individuals
- Uses heterogeneity as an assumption, not homogeneity
- Minimizes or exposes power imbalances
- Rejects androcentric models as normative
- Challenges the medicalization and pathologizing of normal physiologic processes
- Seeks social and political change to address health issues

attributes of being a woman (such as reproductive capacity and feminine appearance). Gender is defined as a person's self-representation as man, woman, or nonbinary and the way in which social institutions respond to that person based on the individual's gender presentation. Gender is often congruent with sex (e.g., a person with female genitalia identifies as being a woman, or cisgender), but it can also be incongruent (e.g., a person with female chromosomes may identify as being a man, or transgender man). Sex and gender are irreducibly entangled from both the research and practice perspectives, however, and are better referred to by the combined term sex/gender, which acknowledges the combined contribution of both the biologic and socially constructed aspects (Springer et al., 2012).

Sex/gender is a socially constructed attribute that is shaped by biology, environment, and experience and is expressed through appearance and behavior (Fausto-Sterling, 2012). Social construction is the process by which societal expectations of behavior become interpreted as innate characteristics that are biologically determined. Thus, behaviors associated with femininity become confused with innately determined behaviors rather than being recognized as socially constructed behaviors. As a result, health risks, treatments, and approaches to care are not necessarily biologically based aspects of health, but rather they are determined by social expectations rooted in assumptions about sex/gender differences. In addition, diagnoses can be influenced by sex/gender assumptions regarding behavior or what is socially constructed as feminine behavior. A significant body of literature has documented such influences on the manner of diagnosis and treatment in mental health (Neitzke, 2016) and obesity (Wray, 2008), as well as in the misdiagnosis of women's cardiovascular risks (Worrall-Carter et al., 2011) and inadequate education to prevent cardiovascular disease in women (Hilleary et al., 2019).

Three primary aspects must be considered when examining the impact of sex/gender on women's health. The first is the priorities assigned to research, treatment, and outcomes in women's health as compared to men's health. The second is the context of sex/gender, including how it affects the process of providing healthcare services, which encompasses an acknowledgment of power differentials. The third aspect is the social construction of sex/gender, including how it affects health. Each aspect has implications for the manner in which people access, receive, and respond to health care. Collectively, these three aspects provide opportunities for us to better understand healthcare experiences and assist in the identification of underlying factors that influence the healthcare disparities experienced by women.

Social role expectations based on sex/gender can create undue burdens for women and may subsequently lead to increased health risks. For example, limited access to all contraceptive options may create reproductive health risks. Extensive cultural preoccupation with dieting and thinness may lead to unsafe dieting practices and precipitate eating disorders. Anorexia and bulimia are more prevalent among women despite the lack of a clear biologic explanation for this predominance.

Another example of a health risk based on sex/gender is the disproportionate amount of violence that women experience (Modi et al., 2014). Gender-based violence includes any act that results in physical, sexual, or psychological harm or suffering (United Nations General Assembly, 1993). The multiple health consequences of violence reveal the persistent layers of health consequences associated with a gender-based health risk. Refer to Chapters 15 and 16 for further discussion of this topic.

INTERSECTIONALITY

Sex/gender interacts with many other identities that affect healthcare delivery and outcomes. Intersectionality is the unique combination of multiple identities based on race/ethnicity, socioeconomic status (SES), sex/gender, nation status, ability, and other factors, as well as the experience of oppression based on these identities. Disparities in health outcomes are often better explained by considering the intersections of multiple forms of oppression based on identity (Etherington, 2015; Warner & Brown, 2011). For example, women of color who are poor often obtain fewer or receive different health services and have worse health outcomes compared to more affluent white women. Although low SES is the single most powerful contributor to illness and premature death (Mehta et al., 2015), numerous examples of poorer health based on race/ethnicity can be cited even after controlling for SES (Williams, 2008; Williams et al., 2016).

Race as a category has been critiqued as creating a false perception of biological difference despite gene-level similarities across defined races. Thus the term “race/ethnicity” is used to describe a socially constructed combination of physical attributes and cultural commonality (Williams, 2008; Williams et al., 2016). Although disparities in health outcomes across race/ethnicities are often assumed to be genetic or biologic, in reality they are significantly impacted by social forces of discrimination. Discrimination is unjust treatment that is based on appearance or identity and is often described primarily as an interpersonal construct (e.g., a person expressing racist opinions). Even more damaging than interpersonal discrimination is systemic or structural discrimination; such injustice perpetuates large-scale, often invisible processes, policies, systems, or structures (e.g., underfunded school systems in poor districts, locations of subsidized housing) that are much harder to dismantle than individual opinions. Structural discrimination impacts the social, political, geographic, and economic influences on health, yet it is very difficult to quantify and often is misidentified (Krieger, 2014).

The structural components of where we live, learn, work, and play impact health across the life span. Where we live encompasses factors such as access to living space with good air quality, access to safe drinking water, access to green space, a safe environment for spending time outdoors, local grocery stores with high-quality fresh food, neighborhood and community support, and even the distance to a place of employment, which dictates the ability to walk to work versus having a lengthy car

commute. Where we learn incorporates factors such as access to well-equipped, safe schools with challenging and engaging curricula that teach skills to prepare students for high-quality employment and future life skills. Where we work reflects access to living wages, safe working conditions, healthcare benefits, and a sense of meaningful work. Where we play includes types of recreation that promote physical activity, community connection, and long-term healthy behaviors such as exercise. Feminist considerations in relation to health disparities in these areas include race/ethnicity and sex/gender bias in hiring, access to resources, availability of healthcare providers, and contraceptive options. Policies or practices that impose undue stress or limit access based on sex/gender contribute to health disparities and are a form of structural bias.

The social embeddedness of health generally, and women’s health specifically, must attend to multiple factors—such as types of medical care, geographic location, migration, acculturation, racism, exposure to stress, and access to resources—when exploring disparities in women’s health. Only by incorporating these factors into the discussion can we fully and accurately appreciate the health disparities women experience, including factors of sexism.

A MODEL OF CARE BASED ON A FEMINIST PERSPECTIVE

A model of care that is based on a feminist perspective contrasts sharply with a biomedical model, particularly in the areas of power and control and also in the definition of what is health compared to pathology. A feminist model supports egalitarian relationships and identifies the person as the expert on their own body. The person is at the center of this healthcare model. The following key points provide further insights into a feminist-based model of care:

- The model of care must focus on *being with*, not *doing for* the person. This frames the model of care as a partnership as opposed to a model of care in which treatment decisions are directed by others and then dictated to the person.
- Heterogeneity, rather than homogeneity, is assumed. Using broad generalizations like “all women,” with their inherent gender-based assumptions, essentializes women rather than acknowledging diversity among individuals and across experiences. An assumption of heterogeneity considers people on an individual basis, tailoring health care and services to each individual’s unique needs rather than treating all females as a group with the assumption of similarity across all considerations of health.
- The feminist model of care seeks to minimize or expose power imbalances that are inherent in most current healthcare models, especially those based on a biomedical model. Power should be distributed equally within the healthcare interaction, and the interaction should be based on a belief in an individual’s right to self-determination and their self-knowledge of their body. Therefore, the role of the clinician focuses on providing support, information, education, and skillful knowledge, as opposed to asserting authority over the decision-making ability of the individual.
- A feminist framework rejects androcentric models of health and disease as normative. The pervasiveness of male-based models being extrapolated and applied to women assumes

that women are merely a biologic variant of men. This misapplication of androcentric models to women's health also serves to medicalize or pathologize normal physiologic processes, such as menstruation, childbirth, and menopause (Lorber & Moore, 2011). In contrast, the feminist model acknowledges as normal those physiologic changes that occur over an individual's life span, such as menarche and menopause.

- A feminist perspective challenges the process of medicalizing and pathologizing by identifying and exploring women's unique health experiences and normalizing them. Medicalization is the process of labeling conditions as diseases or disorders as a basis for providing medical treatment. The medicalization of biologic functions, such as menstruation, pregnancy, and menopause, is frequently cited as an illustration of both the social construction of disease and the general expansion of medical control into everyday life (Conrad, 1992; Zola, 1972). In addition, characterizing behaviors that are not gender normative as potential pathology, instead of appreciating the social context in which they occur, serves as a form of pathologizing. Examples are defining sexual desire using androcentric models and then developing treatments for it without considering the potential for coercion or a prior history of sexual trauma.
- A feminist framework acknowledges the broader context in which individuals live their lives and the subsequent challenges to their health as a result of living within a patriarchal society. It argues for a process of social and political change that would eliminate gender bias and sexism. This includes consideration of how the personal health decisions and healthcare interactions a woman experiences are influenced by the larger structural and political context in which people live their lives, including access to services and resources.

SOCIAL MODELS VERSUS BIOMEDICAL MODELS OF HEALTH

As the discussion of the social construction of sex/gender and its relationship to health unfolds, it becomes evident that a broader model of health must be employed to address the health consequences of gender bias and sexism and their implications for overall health and well-being. The first step in broadening the model of health requires redefining health itself. Health is biomedically defined as the absence of disease—a narrow definition that does not address the context in which the absence of disease may occur. Considering only the absence of disease fails to address quality of life or the opportunity to reach the individual's potential. To gain a fuller appreciation of the scope of health, the dominance of the medical model as the rubric that defines health must be challenged in an effort to broaden the lens of what is health and to expand its definition. Without a broader definition, opportunities to understand the social realities and complexities within the healthcare system and the experiences of health for an individual and the collective community will remain limited. Without a broader perspective, which aspects of health are understood or studied will also be limited to individual characteristics or behaviors devoid of the context in which those behaviors and/or experiences are occurring. The biomedical model, as a conceptualization of health, generally does not address health beyond an individual perspective.

An alternative to the biomedical definition of health is offered by the World Health Organization (WHO, n.d.), which defines health as “a state of complete physical, mental, and social well-being and not merely the absence of disease or infirmity.” This broader definition is based on assumptions of what must be present to secure health for individuals and the community in which they live. It addresses the social context in which individuals live their lives, including the communities where they live, work, and play. According to WHO, the following prerequisites must be in place before health can occur:

- Freedom from the fear of war
- Equal opportunity for all
- Satisfaction of basic needs for food, water and sanitation, education, and decent housing
- Secure work
- Useful role in society
- Political will
- Public support

Germane to this definition is the commitment to address social injustice, equity, economic development and opportunity, and accessibility of healthcare services as a basic human right for all individuals in any society. WHO's definition of health requires that the community and environment in which women live must also be considered in the same context as a new medical procedure. The constraints of an individualistic biomedical model of health that focuses only on disease become readily apparent when WHO's broader context and definition of health are considered. Through the use of this definition of health, the social aspects of health and the contributors to health are acknowledged, broadening the lens to include factors that must be addressed to support individual and collective health.

A social model of health is more congruent with a feminist perspective, compared to the biomedical model. The social model of health expands the contributors to health beyond just the individual body, extending them to the family, community, and society. This broader perspective enhances the understanding of health disparities that are rooted in the social and cultural forces that affect how individuals live their lives.

The interconnectedness of working and living conditions, environmental conditions, and access to community-based healthcare services becomes a focus when health and well-being are framed within a social context. Questions about health and well-being for an individual home in on these factors as well as lifestyle decisions and health habits. The prevention of health problems becomes both a social burden and an individual responsibility. This wider emphasis, in turn, forces greater consideration of the various social factors that can either support or degrade an individual's health.

A social model of health also requires asking questions about the health effects of socially situated factors such as racism, sexism, and other forms of oppression. Consideration of women as central to the health model, rather than marginal to it, is a requirement of the feminist social model of health care. The broader social models do not ignore biologic or genetic components of health, nor is the significance of individual lifestyle health habits denied. However, the broader social model frames these issues as important to health, but no more so than experiences within everyday life, access to healthcare services, SES, racial/ethnic identity, and membership within a community (Schiebinger, 2003).

The health risks associated with the social construction of sex/gender and the inequities associated with gender-based assumptions are essential components of the feminist social model of health. As links are forged among human rights, social models of health, health disparities, and opportunities to address those disparities, a feminist perspective offers new strategies and ways of thinking or asking questions that can promote expanded approaches to health issues.

FEMINIST STRATEGIES FOR THE ANALYSIS OF HEALTH

Several aspects of analysis are important when considering health from a feminist perspective. The following strategies for analyzing health using a feminist framework are adapted from Franz and Stewart's (1994) strategies for conducting feminist research. Each of the strategies listed in **Table 1-1** can be used to form a question one can ask about health issues. Taken together, they constitute a feminist lens that allows for new considerations to arise as health issues are reframed. The following discussion highlights the manner in which some of the strategies can be applied.

Look for What Has Been Left Out or What We Do Not Know

This strategy is particularly applicable to investigations into the scientific basis of women's health. Much of what we know about women's health needs, outside of reproductive health, is historically based on androcentric models of men's health considerations. For many years, almost all medical research that was not related to gynecology was conducted using male participants (human and animal), with the findings then being generalized to women. Large-scale investigations focusing on health promotion have been based primarily on study populations composed of only men. This approach was consistently practiced until the 1990s, but it continues to be an issue (Pinnow et al., 2014; Schiebinger, 1999).

According to feminist scientist Londa Schiebinger's analysis, many common health promotion measures have been assumed to be true for both men and women despite the fact that the evidence supporting the measures came from research in which the study populations included only men. Examples of such studies include the Physicians' Heart Study, in which the findings led to recommendations on the use of aspirin to prevent heart disease, and the Multiple Risk Factor Intervention Trial, which evaluated correlations among blood pressure, smoking, cholesterol, and heart disease. In fact, one of the first studies to investigate the use of estrogen for heart disease was conducted on a study population consisting of only men (Schiebinger, 2003)!

The lack of women being represented in research trials reflected a prioritization of men's health issues and was also rooted in gendered assumptions about the potential impact of research on women's reproductive capacity. Additional considerations focused on women's hormonal variations throughout the menstrual cycle as potentially challenging issues in studies of medications. These and other biases related to women's participation as research participants extended through 1988, when clinical trials of new drugs were routinely conducted predominantly on men, even though women consume approximately 80 percent of the pharmaceuticals in the United States

(Schiebinger, 2003). In employing one of the feminist strategies, the question of what has been left out can be asked, and the answer is considerations of women's biologic variations in processing drugs. The significance of potential hormonal variations was not considered in exploring the impact of particular treatments on women or was not factored into study designs. For example, acetaminophen is eliminated in women at 60 percent of the rate at which it is eliminated in men. This finding obviously has sex/gender-related implications for prescribing dosage regimens. Alternatively, it should not be assumed that all medications will have variations or that variations in dosing regimens are the same for all women because women after menopause may be more similar to men than they are to women who are menstruating.

Examples abound of the problematic manner in which the scientific base for women's health, beyond reproductive health, was initially developed. Even when positive study examples are cited, limitations were often present in the design of the studies. Many key women's health studies, such as the Framingham Heart Study and the Nurses' Health Study I and II, were either observational or epidemiologic investigations instead of randomized clinical trials, even though the latter design has long been considered the gold standard for investigative research (Schiebinger, 2003). Examples such as these suggest that women were being left out of the scientific quest to understand many health issues that directly affected them.

Consumer health advocates, women's health activists, and members of the scientific community have been instrumental in coming together to address the many limitations concerning women's health care and scientific investigations of women's health issues. In 1993, the National Institutes of Health's (NIH) Revitalization Act was considered a milestone in this regard. The Revitalization Act required that women and minorities, and their subpopulations, be included in all NIH-supported biomedical and behavioral research, including phase 3 clinical trials, in numbers adequate to ensure valid analysis of differences in intervention effects; that the cost not be the basis for exclusion from clinical trials; and that outreach programs to recruit these individuals for clinical trials are adequately supported. As a result of this policy change, important progress has been documented in terms of significantly greater inclusion of women and minorities in research investigations. In this case, asking what had been left out or what was missing provided an opportunity to alter what had been left out of women's health research.

There is an ongoing need to employ this strategy to expose blind spots in what is being presented under the rubric of women's health. An example can be found in the current focus on heart disease in women. Heart disease is now the most common cause of mortality among US women. Every step in the healthcare process related to cardiovascular disease—from identification of symptoms to diagnosis, treatment, and referral—demonstrates sex/gender-related differences. The need to explore this disease process in women becomes even clearer when the question of what has been left out of prior studies is asked. The answer has helped frame new ways to address this heart or cardiovascular disease in women. Rather than accepting the inappropriate misapplication of findings to women when research was conducted only in men, researchers are being charged with exploring new avenues of research and new ways of asking the research question.

TABLE 1-1

Strategies for Analysis of Health from a Feminist Perspective

Strategies	Questions
Look for what has been left out or what we do not know.	<ul style="list-style-type: none"> • What do we know, how do we know it, and who knows it? • Why don't we know? What do we want to know and why? • Who determines what is left out or who has access to what we want to know?
Analyze your own role or relationship to the issue or topic.	<ul style="list-style-type: none"> • Is it personal? What is the meaning of this issue for you as an individual? • Is it political? What is the meaning of this issue for you as a woman or as a member of an identified group? • Depending on your relationship to the issue, can you be objective in its analysis or are you engaged personally and subjective? • Are you invested in the outcome or topic or not? • Why do you care about the issue?
Identify a person's agency in the midst of social constraints and the biomedical paradigm.	<ul style="list-style-type: none"> • Are people really just victims, or are they acting with agency? • Are individuals making choices despite positions of powerlessness? • Are the choices allowing individuals to remain in control, or do they allow individuals to have some form of power in the context of the situation? • By identifying a person's agency in a particular context, can we learn new ways of understanding or approach to the health implications?
Consider the social construction of sex/gender and how its assumptions may be used to define what health is, limit options, or presume which behaviors and/or choices can be made within the context of health.	<ul style="list-style-type: none"> • Explore gendered assumptions about the value of anatomy such as breasts or facial appearance. • Would this health issue be defined or explored in the same manner if it primarily affected one sex or another? • Do socially prescribed gender norms influence how this health condition is understood or defined (e.g., mental health)?
Explore the precise ways in which sex/gender defines or affects power relationships and the implications of those power dynamics in terms of health.	<ul style="list-style-type: none"> • Physician/nurse • Clinician/patient • Parent/adolescent • Husband/wife • Parent/child • Father/daughter • Partnered or not partnered woman • Heterosexual/transgender
Identify other significant aspects of an individual's or group's social position, and explore the implications of that position as it relates to health issues.	<ul style="list-style-type: none"> • Consider examples such as an adolescent who is seeking reproductive healthcare services or a same-sex couple seeking fertility services. • Ask who has access to various forms of healthcare services and resources and who does not. • Consider the intersections of race, class, gender, sexuality, and socioeconomic status. • Who has a choice, what constitutes a choice, and who is able to exercise the right to make choices within the context of health?
Consider the risks and benefits of generalizations and speaking in terms of groups versus individuals.	<ul style="list-style-type: none"> • Who are "all women"? Are "all women" the same? • Consider who benefits from generalizations or assumptions of homogeneity versus heterogeneity. • Is value placed on having a coherent understanding of a health issue compared to acknowledging diversity or complexity in how the issue is experienced? • Which reflects reality most accurately—a coherent story or an appreciation for diversity in the understanding of the health issue? • When "grouping" occurs, who is missing from the group or who might not be reflected in the group process?

Information from Franz, C., & Stewart, A. (Eds.). (1994). *Women creating lives: Identities, resilience, and resistance*. Westview Press.

Analyze Your Own Role or Relationship to the Issue or Topic

Traditionally, the focus on women's health has been relegated to systems between the breasts and the knees. Pregnancy and childbirth were long the focus when it came to health care of women because the value of women was based on their role in

procreation and continuation of the citizenry. Historically, this focus on reproductive health created opportunities to promote maternal and child health reforms in the public health arena. In such cases, women typically took advantage of the focus on reproductive health to advance an agenda that addressed both maternal and child health. At the same time, the practice

of addressing only reproductive health carried risks because it enabled normal physiological reproductive processes to be medicalized within a biomedical context.

In response to the practice of medicalizing aspects of women's health and traditional models of women's health care, consumer activism by women has been directed at reframing women's health and calling for reforms at even the most basic levels. The strategy of analyzing your own role or relationship to the issue may help reveal the role women play in relation to the process of rejecting medicalization of many normal, healthy physiologic processes they experience.

Over the past 50 years, aspects of women's health have been topics of public debate and of organized social action. Two notable waves have occurred in the women's health movement. One wave coincided with social action movements, such as the civil rights and women's rights movements. A key feature of this wave was its grassroots orientation, with a key focus on access to information and expanded knowledge regarding health. One outgrowth of this movement was the creation of the Boston Women's Health Book Collective (BWHBC) and its publication of *Our Bodies, Ourselves* for consumers in 1974. During this period, primary access to health-related information was available only through medical textbooks. In contrast to this historical practice in which women's health information and knowledge was framed as reserved for the domain of medical professionals, particularly physicians, the BWHBC promoted open access to health information for women as consumers. Members of the BWHBC were consumers who sought out information prior to the advent of the internet and readily available online access. Arguably, they were the forerunners to the wealth of accessible online health information sources that are available today. The BWHBC's membership included women who were health-care consumers; they developed a consumer-oriented women's health book through a process of conducting individual research related to women's health. The framework that the BWHBC used was one of reclaiming health for themselves, using the feminist perspective of reducing power differentials to access information. Knowledge about health empowered women to seek out services, redefine what health was, and consider a wider range of treatments or choices they might not have otherwise been exposed to or offered.

With this wave of health activism came a strong rejection of the medicalization of physiologic processes, with women reclaiming control of their health by offering new definitions. A key aspect of this ongoing process is the demystification of health conditions and processes to promote women's agency and autonomy and empower them to engage effectively with clinicians. This change supported women in taking control of their health away from medical professionals and assuming responsibility for their healthcare decision making, rather than simply adhering to the older biomedical model, which placed authority for decision making firmly under the control of the clinician. The BWHBC was an initial pioneer in this movement, as was the Women's Health Network.

Although this phase of the women's health consumer movement in the 1970s and 1980s was, in many ways, pivotal in defining a women's health agenda, it also lacked an appreciation of intersectionality and diversity. Essentially, this wave of the women's health movement could be critiqued as assuming homogeneity of women's health issues rather than heterogeneity. In response, the National Black Women's Health Project

was launched in 1983 by Byllye Avery, with the goal of understanding Black women's health issues in the broader social context. This project, which was eventually renamed the Black Women's Health Imperative, remains the only national organization dedicated to improving the health and wellness of Black women (Black Women's Health Imperative, 2015). Importantly, this organization defines its goal as addressing health and wellness through a framework that includes physical, emotional, and financial aspects, thereby incorporating social considerations and the biological elements of health. According to some scholars, the launch of this project was not intended as a rejection of the importance of other women's health organizations, but rather it highlighted the need for independent organizations to frame questions or areas of emphasis that were unique to them while also opening opportunities for collaboration in collective areas of interest (Hart, 2012). From a practical standpoint, this meant that instead of everyone working within one organization on what presumably are issues for all women's health, individual organizations, representing and defined by various groups, could organize to address their specific health concerns. However, the various organizations could build alliances and coalitions with one another when issues of common interest were identified (Hart, 2012).

The ongoing efforts directed toward close examination of how the intersections of racism and sexism affect health disparities are essential to disentangling the social determinants of health and how they impact overall health outcomes for women of color in particular. Asking the question of how a health issue relates to you personally or politically is an important first step in considering that issue's significance, but it is also important to consider how individual factors can or cannot be extended in making assumptions for a larger population of women.

Consider the Risks and Benefits of Speaking in Terms of Groups versus Individuals

Reclaiming control of women's health care from clinicians and focusing on women's role and authority over their own health was initially promoted by well-educated white, straight, cisgender women from middle- and higher-income groups. This limited view within the women's health movement revealed the problematic underpinnings of presumed homogeneity across all women.

The strategy of considering the risks and benefits of speaking in terms of groups versus individuals acknowledges this problematic aspect of the women's health movement. Today, women's health activists demonstrate greater diversity and focus on a wider range of issues that affect the health of women and their families.

Consider the Social Construction of Sex/Gender and How Its Assumptions May Limit Options or Presume Choices That Are Made within the Context of Health

Earlier discussions regarding the social construction of sex/gender highlighted the implications of this strategy. An additional aspect to consider is the manner in which women's health issues are described; that is, the terminology used. The language used for many women's health concerns has been described by anthropologist Emily Martin (2001) as reflecting an androcentric bias; for example, the image of menstruation in medical texts is that of "failed reproduction" (p. 92).

Another example is the practice of referring to a woman who has experienced sexual assault as a victim rather than a survivor, implying inherent weakness rather than strength. Descriptions of childbirth usually invoke the term “delivery”; that is, a woman being *delivered* rather than *giving birth*. The “delivery” terms focus on the actions of the clinician and place the woman in a passive position, rather than appreciating her as the central figure: the one giving birth.

Explore the Precise Ways in Which Sex/Gender Defines Power Relationships and the Implications of Those Power Dynamics on Health

Creating health care from a feminist perspective requires the acknowledgment of power differentials between individuals who are consuming health care and those who provide it (clinicians). It also mandates attempts to minimize power differentials by developing a partnership model of care provision. In this model, rather than invoking a level of authority by virtue of being a clinician, the clinician acknowledges the life experiences and knowledge that the person brings to the interaction. What makes a practice feminist is not who provides the health care, but rather how that care is provided, how the clinician thinks about their work, and which populations the clinician works with.

Hierarchical relationships and structures are typically elements of the traditional healthcare delivery system, but feminist practice requires an active process of action to decrease asymmetrical relationships. Examples of simple actions include not having a person undress prior to meeting the clinician so the individual can greet the clinician as an equal rather than from a vulnerable position (naked and wrapped in an ill-fitting paper gown); and having a person check their own weight, as opposed to having someone else do it, to place some accountability for health on their shoulders. These actions send the message that the person can control aspects of their healthcare experiences. Although these simple changes can be readily made in the healthcare office setting, each demonstrates power sharing rather than placing the patient in a dependent position for aspects of her health care that she should rightly control.

Additional ways for clinicians to address gender dynamics and power relationships include supporting a feminist model of care that focuses on the ways in which the healthcare interaction is addressed. Key features of this model deal with how one listens and trusts what the person brings to the interaction. These steps include removing assumptions from consideration and not ascribing meaning without confirming it directly with the person. Checking power imbalances and addressing them, even simply by means of introduction and the manner in which the clinician sits in relation to the person, can give them greater power in

the relationship. Careful use of language and terminology must occur in all discussions and information that is provided. Seeking consent before touching and assuring the person has control over what is or is not done during an examination is required. For additional considerations of promoting a feminist approach to healthcare interactions, see the blog *Feminist Midwife* (<http://www.feministmidwife.com/>).

Each of the strategies discussed in this chapter provide an opportunity to consider the details and the global aspects of health care and women's health issues. These strategies can be applied both individually and collectively. They are not meant to be an exhaustive checklist to determine whether something is being considered from a feminist perspective, but rather are meant to serve as guidelines and considerations that allow for the identification of blind spots in how we are able to think about health issues when we are potentially constrained by the limitations of the biomedical model. Through the use of these strategies, clinicians, policy makers, and women themselves are able to reframe expectations, approaches, and the focus of health research, healthcare delivery, and receipt of healthcare services.

WHY A TEXT ON GYNECOLOGY?

Taking the same feminist strategies we use for analyzing women's health and applying them to this text on gynecologic aspects of health creates opportunities. Why, when a feminist perspective is being presented, along with the limitations of considering women's health as being equivalent to reproductive health, would a text purportedly using a feminist framework focus primarily on the gynecologic aspects of health? The reason is that gynecologic health is still important. Focusing on gynecology for clinicians is important because reframing and expanding considerations of gynecologic health from a feminist perspective may more accurately reflect the experience of gynecologic health for people in their everyday lives. By offering a feminist perspective throughout the chapters in this text, we seek to dispel myths that pathologize normal gynecologic functioning, and we seek to support normality as opposed to medicalizing it. We also offer a framework for providing gynecologic health care that considers the social, emotional, and intimate and physical nature of this aspect of health care. Rather than ignoring gynecologic health and allowing it to remain within the biomedical domain, this text seeks to reframe aspects of gynecologic health issues within a feminist framework. This perspective expands the opportunities for understanding gynecologic health within a wellness-oriented, person-centered framework that considers both the social and the biologic elements and encourages clinicians providing health care to look beyond the medical model and to *support* normalcy instead of *manage* it.

References

- Black Women's Health Imperative. (2015). *Our story*. <https://bwhi.org/our-story/>
- Boston Women's Health Book Collective. (1974). *Our bodies, ourselves*. Simon & Schuster.
- Conrad, P. (1992). Medicalization and social control. *Annual Review of Sociology*, 18, 209–232.
- Erkison-Schroth, L. (Ed.) (2014). *Trans bodies, trans selves: A resource for the transgender community*. Oxford.
- Etherington, N. (2015). Race, gender, and the resources that matter: An investigation of intersectionality and health. *Women and Health*, 55(7), 754–777.
- Fausto-Sterling, A. (2012). *Sex/gender: Biology in a social world*. Routledge.
- Franz, C., & Stewart, A. (Eds.). (1994). *Women creating lives: Identities, resilience, and resistance*. Westview Press.
- Hart, E. (2012). *Building a more inclusive women's health movement: Bylye Avery and the development of the National Black Women's Health Project, 1981–1990* [Doctoral

- dissertation, University of Cincinnati]. OhioLINK. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1342463625
- Hilleary, R. S., Jabusch, S. M., Zheng, B., Jiroutek, M. R., & Carter, C. A. (2019). Gender disparities in patient education provided during patient visits with a diagnosis of coronary heart disease. *Women's Health, 15*. <https://doi.org/10.1177/1745506519845591>
- hooks, b. (2000). *Feminism is for everybody*. South End Press.
- Krieger, N. (2014). Discrimination and health inequities. *International Journal of Health Services, 44*(4), 643–710.
- Lorber, J., & Moore, L. J. (2011). *Gendered bodies*. Oxford University Press.
- Martin, E. (2001). *The woman in the body: A cultural analysis of reproduction*. Beacon Press.
- Mehta, P. K., Wei, J., & Wenger, N. K. (2015). Ischemic heart disease in women: A focus on risk factors. *Trends in Cardiovascular Medicine, 25*(2), 140–151.
- Modi, M. N., Palmer, S., & Armstrong, A. (2014). The role of Violence Against Women Act in addressing intimate partner violence: A public health issue. *Journal of Women's Health, 23*(3), 253–259.
- Neitzke, A. B. (2016). An illness of power: Gender and the social causes of depression. *Culture, Medicine, and Psychiatry, 40*, 59–73. <https://doi.org/10.1007/s11013-015-9466-3>
- Pinnow, E., Herz, N., Loyo-Berrios, N., & Tarver, M. (2014). Enrollment and monitoring of women in post-approval studies for medical devices mandated by the Food and Drug Administration. *Journal of Women's Health, 23*(3), 218–223.
- Schiebinger, L. (1999). *Has feminism changed science?* Harvard University Press.
- Schiebinger, L. (2003). Women's health and clinical trials. *Journal of Clinical Investigation, 112*(7), 973–977.
- Springer, K. W., Stellman, J. M., & Jordan-Young, R. M. (2012). Beyond a catalogue of differences: A theoretical frame and good practice guidelines for researching sex/gender in human health. *Social Science Medicine, 74*(11), 1817–1824.
- United Nations General Assembly. (1993). *Declaration on the elimination of violence against women*. https://www.un.org/en/genocideprevention/documents/atrocities-crimes/Doc.21_declaration%20elimination%20vaw.pdf
- Warner, D. F., & Brown, T. H. (2011). Understanding how race/ethnicity and gender define age-trajectories of disability: An intersectionality approach. *Social Science Medicine, 72*(8), 1236–1248.
- Williams, D. R. (2008). Racial/ethnic variations in women's health: The social embeddedness of health. *American Journal of Public Health, 98*(9), S38–S47.
- Williams, D. R., Priest, N., & Anderson, N. B. (2016). Understanding associations between race, socioeconomic status and health: Patterns and prospects. *Health Psychology, 35*(4), 407–411. <https://doi.org/10.1037/hea0000242>
- World Health Organization. (n.d.). *What is the WHO definition of health?* <https://www.who.int/about/who-we-are/frequently-asked-questions>
- Worrall-Carter, L., Ski, C., Scruth, E., Campbell, M., & Page, K. (2011). Systematic review of cardiovascular disease in women: Assessing the risk. *Nursing and Health Sciences, 13*(4), 529–535.
- Wray, S. (2008). The medicalization of body size and women's healthcare. *Health Care for Women International, 29*(3), 227–243.
- Zola, I. (1972). Medicine as an institution of social control. *Sociological Review, 20*, 487–504.

Racism and Health Disparities

Elizabeth Donnelly

Van D. Dao

Carline Wilson Mitchell

Jynelle Ede Wren

INTRODUCTION

People of color, especially Black and Indigenous people, suffer from gross inequities in health. These health inequities are the embodiment of racism. The aim of this chapter is to help clinicians address disparities that are rooted in racism by understanding and being prepared to address racism. The chapter begins with key concepts and definitions to ensure all readers have a common language. This is followed by a brief history of the development of racism in the United States. The chapter describes a range of theories, frameworks, and concepts for understanding and addressing racism in health care, and it provides an overview of race-associated gynecologic health disparities data. The final section of the chapter presents key interventions for addressing racism and related disparities.

Author Reflexivity

All people in the United States are born into and grow up with the constructs of racism permeating our experience. The authors of this chapter are no different. Even as a multiracial group with a collective commitment to antiracism, each of us has our own bias and areas for growth. We recognize that dismantling this system requires collective effort. With that in mind, we give thanks to those who supported the development of this chapter, especially Juana Rosa Cavero, California Coalition for Reproductive Freedom; Lisa Fu, MPH, California Healthy Nail Salon Collaborative; Patricia O. Loftman, CNM, LM, MS, FACNM; Felina M. Ortiz, DNP, CNM; and Aisha Mays, MD, Director of Adolescent and School-Based Health Services, and Founding Director of the Dream Youth Clinic Roots Community Health Center.

Even with this collective effort, we recognize that there may be content within this chapter that may unintentionally reinforce the very structures we aim to dismantle. We humbly ask that readers of this chapter keep an open mind and a critical eye. If you recognize room for growth in this chapter, share this with your fellow students and the authors. It is only by working together and bringing each other along that society will dismantle the systems that privilege the few at the expense of the many.

KEY CONCEPTS AND DEFINITIONS

Health Equity and Health Disparities

Gross inequities in human society are responsible for preventable death and morbidity of millions of people (Commission on

Social Determinants of Health, 2008). Achieving optimal health, reducing unconscionable premature loss of life, and averting preventable health conditions requires working toward equity not just in clinical care, but also in society. This work requires understanding health equity and health disparities.

“Health equity is the ethical and human rights principle that motivates us to eliminate health disparities, which are differences in health or its key determinants (such as education, safe housing, and freedom from discrimination) that adversely affect marginalized or excluded groups. . . . Equity is not the same as equality; those with the greatest needs and least resources require more, not equal, effort and resources to equalize opportunities” (Braveman et al., 2018, p. 3). See **Figure 2-1** for a depiction of this concept. To achieve health equity, it is critical that healthcare providers understand the social, political, and institutional structures and the interpersonal relationships that impact individuals’ and communities’ health, values, and relationship to health care. Healthcare providers must also understand how these forces shape their personal life experiences and impact their approach to the provision of health care and how healthcare professions and institutions are shaped by these forces.


“Health disparities” is the term used to describe the differences in health that adversely affect communities that are socially and/or economically disadvantaged. It is important to note that a health disparity is not simply a health difference, but rather a difference that is plausibly avoidable and impacts individuals from communities that are socially, politically, and/or economically disadvantaged, such as people who are lesbian, gay, bisexual, or queer, transgender, immigrant, poor, disabled, and/or of color (Braveman et al., 2018).

Power, Privilege, Oppression, and Intersectionality

Individuals from socially, politically, and/or economically disadvantaged communities are not inherently disadvantaged. Instead, their inequality is the result of political and social structures that create and maintain hierarchical relationships among social groups. These hierarchical relationships ensure that individuals from certain social groups, such as people who are cisgender, male, heterosexual, and/or white, have greater access to power. Power is the ability to direct or influence the behavior of others, oneself, or a course of events (Givens et al., 2018). When power is unearned and unfairly advantages some people over others, it is called privilege. When certain groups

FIGURE 2-1

Equality and equity.



To achieve equity, some individuals and communities need more and/or different resources. Equality is depicted in the image on the left, which shows each person receiving the same resources in the form of a single box. This results in the person on the left easily viewing the game, while the two people on the right have an obstructed view. Note that the two people on the right side of these images are depicted as being on ground that slopes down and behind a fence that slopes up, both of which combine to restrict their access to watching the game. The ground and fence illustrate the structural nature of inequity. In the image on the right, equity is represented by the increasing number of boxes under the people so that all three individuals can easily view the game. Note that all of the people have similar heights to indicate comparable inherent abilities.

Reproduced from Kuttner, P. (2015). The problem with that equity vs. equality graphic you're using. <http://culturalorganizing.org/the-problem-with-that-equity-vs-equality-graphic/>. © Copyright 2015, Paul Kuttner.

are systematically denied access to power, it is called oppression. Privilege and oppression grant variable and inequitable access to social, political, and economic resources, such as wages, high-quality education, safe housing and communities, and comprehensive health care, which results in variable and inequitable access to power.

It is important to note that this discussion refers to population-level effects. The fact that “some individuals in an excluded or marginalized group may have escaped from some of the disadvantages experienced by most members of that group . . . do[es] not negate the fact that the group as a whole is disadvantaged in ways that can be measured” (Braveman et al., 2018, p. 4). Similarly, the fact that some people from privileged social groups may experience disadvantage does not negate the privilege experienced by the group as a whole.

Further, each individual is a unique mix of social identities and the interactions among those identities (e.g., race, ethnicity, gender, class, sexual orientation, age, disability/ability, migration status, religion) (Bowleg, 2012; Hankivsky, 2014). In some individuals, a socially privileged identity may moderate the disadvantages of a socially oppressed identity. In other cases, individuals who have multiple socially oppressed identities may experience disparities that are different than those found at the population level of any single disadvantaged group. The compounding effect of having multiple socially oppressed identities

is called intersectionality. The term was coined by Crenshaw (1994) in her work describing the unique challenges faced by Black women in sex and race discrimination legal cases because they were both Black and women. Black men did not face the same gendered experiences as Black women, and white women did not face the same racialized experiences as Black women. The Black women she was representing experienced unique racialized and gendered discrimination.

Race and Racism

Understanding the role racism plays in health inequities requires a shared understanding of the concepts of race and racism. In this chapter, race is defined as social classification of people based on a combination of phenotype, culture, and family and social history. This definition recognizes that race is a multifaceted social construct; there are no biological or genetic markers that map directly onto the socially constructed definitions of race (Williams & Sternthal, 2010). This chapter uses the definition of racism described by Jones (2002): “Racism is a system of structuring opportunity and assigning value based on phenotype (‘race’), that unfairly disadvantages some individuals and communities, unfairly advantages other individuals and communities, and undermines realization of the full potential of the whole through the waste of human resources” (p. 10).

Racial Descriptors

It is important for readers to be aware of the language the authors of this chapter use to describe different racial groups. Because race is a social construct, the terms used to describe different groups and the boundaries of these groups change over time. For example, “Subcontinent Indians were counted as Hindu in three censuses (1920–1940), but as white in the next three censuses. In 1980 they were counted as Asian, a status they retain today” (Prewitt, 2005, p. 7). Even people who would commonly be recognized as white in the current era, such as Irish and southern and eastern Europeans, have been “defined as ‘others’ at one point or another and have been associated with inferior physical, mental, and moral attributes in relation to the dominant white population” (Sáenz & Morales, 2019, pp. 165–166). Much of the evolution of formal language used to describe race is a reflection of efforts to maintain the racial hierarchy for the benefit of those in power (Prewitt, 2005; Snipp, 2003). Thus, it is important to be clear about the terms used in this chapter and why the authors chose to use them.

Throughout this chapter the authors use the term “people of color” as an umbrella term to describe all people not currently racialized as white in the United States. The term encompasses people from a wide range of racial, ethnic, and cultural identities. Because US society operates within a racial hierarchy that privileges white people above others, it can be helpful to view the experiences of people who are not racialized as white together when describing the impacts of racism generally. However, the term “people of color” completely loses its power when it is used instead of a more precise term (e.g., using “people of color” instead of “Black” or “African American” to describe the people of the African diaspora).

As for words that describe specific communities, the authors intentionally use a variety of terms within this chapter to recognize that racial categorization is challenging and imperfect. Racial categories can be externally imposed, internally developed, or developed through a process that is a combination of social interactions, self-identification, and others perceptions (Lemelle, 2011). This chapter uses dual terms for individual racial categories, including African American and Black, Native American and Indigenous, and Hispanic and Latinx. The authors recognize that some individuals will identify with both terms, while others may self-identify with a single term. The hope is to be inclusive of the wide range of ways that individuals identify and to help demonstrate the challenge of language for describing socially constructed racial groups. In the interest of preserving any terms of self-identification, and in an attempt to offer the richest level of data and information to readers, when applicable this chapter uses terms cited in the primary references. Readers will also note throughout the chapter that “white” is the only racial term that is lowercased, while other ethno-racial terms are capitalized. The authors agree with Kapitan’s position that “general editorial standards may call for equal treatment when it comes to the words *Black* and *white*, but until equal treatment exists in our larger society, calls for equal treatment in language only serve to whitewash cultural context, identity and history” (2016, para. 4).

The US census and much scientific research makes a distinction between race and ethnicity for Hispanic people. This distinction is not typically made of any other people when collecting or reporting population-level data. Census categories, also used in health science research, identify race as white, Black or African

American, American Indian or Alaska Native, Asian, and Native Hawaiian or Other Pacific Islander. Respondents are asked to identify their ethnicity (Hispanic or non-Hispanic) and their race separately. Ethnicity is typically understood to refer to people who share common ancestry, language, and other cultural attributes (Sáenz & Morales, 2019; Temkin et al., 2018). When a distinction is made between race and ethnicity, race is described as being primarily related to physical attributes. However, attempts at distinguishing between these two concepts are fraught with difficulties; it is clear that many people who identify with a shared race also share ancestry, language, and other cultural attributes. Because this chapter is focused on the impact of racism on health, the authors have chosen to use the language of race throughout. Ethnicity is mentioned only when that language was used by the underlying study.

Lastly, the authors have chosen to use the term “race-associated disparities” instead of “race-based disparities.” The latter term reinforces the false idea that race, not racism, is the cause of the disparities. The disparities seen in research are associated with individuals’ race, but the basis of this disparity is the individuals’ exposure to racism, not their race.

HISTORY

The Development of Racism in the United States

“The variable ‘race’ is not a biological construct that reflects innate differences, but a social construct that precisely captures the impacts of racism” (Jones, 2000, p. 1212).

This section presents an overview of the development and maintenance of pro-white/anti-Black racism in the United States. It is beyond the scope of this chapter to provide a complete and in-depth presentation of all people’s history with respect to the construction of race and the development of the system of racism in the United States. This section focuses on the development and persistence of anti-Black racism because it is deeply embedded in how race is more generally constructed in the United States. By understanding the construction of anti-Black racism, readers can more deeply understand other forms of racism. However, a risk of sharing this story alone is that it plays into the perception that racism is something that occurs only to Black people and that it is perpetuated only by white people. Of course, this misses the experiences of wide swaths of people in the United States. It is the authors’ hope, however, that sharing this brief introduction to the history of the construction of race for one people can deepen readers’ understanding of the environment in which healthcare providers practice and that it will encourage readers to be aware of the need to further their understanding with respect to other communities.

Humans have long identified differences between those who share their own group identity and those who do not (i.e., in-group and out-group) based on cultural practices, geographic location, language, and other identifying factors. Within this framework, the concept of race was first developed by slave traders to justify and support the development of the African slave trade (Kendi, 2016). The slave traders created the notion of an inferior “Black race” that encompassed all people from the phenotypically, lingually, geographically, and culturally diverse communities of Africa. With this racial construct in place, they justified slaving expeditions by suggesting that slavery and exposure to Christianity was an improvement over freedom in Africa

- adoption
 - infertility, 396
 - options, 371–372
- Affordable Care Act, 76, 149
- age
 - cervical cancer and, 576
 - sexual assault, 326–327
 - urinary incontinence and, 480, 490
- AIDSinfo website, 465
- AIs. *See* aromatase inhibitors
- alcohol misuse
 - counseling interventions for women, 81–82, 83f
 - preconception care, 662
- alcohol screening, 151–155
- allergic contact dermatitis, 547, 549t
- allergies, 104
- alopecia, 530–531
- alpha (α) levels, 61
- amenorrhea, 519
 - management, 524–525, 525t
- American Academy of Physician Assistants, 368b
- American Association of Sex Educators, Counselors, and Therapists, 364
- American Cancer Society, 152–154t
- American College of Emergency Physicians, 331
- American College of Nurse-Midwives, 368b
- American College of Obstetricians and Gynecologists, 152–154t, 296, 368b
- American Physical Therapy Association, 364
- American Psychological Association, 500
- American Urological Association Foundation, 354
- amino acid L-lysine, 449
- amniocentesis, 699
- amniotic fluid, 708
- anatomy and physiology, 87–98
 - breasts, 93–94
 - genitalia, 90–93, 90f, 92f
 - infertility, 384–385
 - male reproductive system, 384
 - menstrual cycle, 94–97, 512t, 519
 - pelvic, 87–89, 88f, 89f
 - postpartum, 713–715
- angiogenesis, 595
- anogenital examination
 - colposcope for, 322, 322f
 - documenting, 322f
 - external genitalia, 322
 - internal genitalia, 322
 - perianal tissue, 321–322
 - steps of, 321b
- anorectal cytology screening, 131
- anovulatory uterine bleeding, 518–519, 518t
- antiandrogens, 537–538
- antibiotic treatment
 - for breastfeeding complications, 724
 - for furuncles and carbuncles, 546
 - for postpartum complications, 724–725
 - for sexually transmitted infections, 324, 443, 457
 - for sexual pain, 363
 - for urinary tract infections, 472, 473t
- antidepressants
 - for postpartum depression, 729
 - and preconception care, 670
- antiretroviral therapy, 465
- anxiolytic drugs, 505
- appendicitis, 608t
- APTA. *See* American Physical Therapy Association
- aromatase inhibitors, 559
- ART. *See* antiretroviral therapy
- ASC-US. *See* atypical squamous cells of undetermined significance
- aspiration abortion, 373–375
- assessment
 - amenorrhea, 519
 - atrophic vaginitis, 420, 421f
 - bacterial vaginosis, 405, 406f
 - bariatric surgery, 166–167
 - Bartholin cyst and abscess, 428
 - breast cancer, 345–346, 346t
 - cervical cancer, 578–579
 - chancroid, 450
 - chlamydia, 453–454
 - desquamative inflammatory vaginitis, 417
 - dyspareunia, 362–363
 - endometrial cancer, 585–586
 - genital herpes, 448
 - genital piercing, 430
 - gonorrhea, 454–455
 - hepatitis B, 462
 - hepatitis C, 463
 - human immunodeficiency virus, 464–465
 - human papillomavirus, 444–445
 - hyperandrogenic disorders, 533–535
 - infertility, 386–392
 - mastalgia, 338–339
 - menstrual-cycle pain and premenstrual conditions, 501, 502t
 - ovarian cancer, 591–592
 - pediculosis pubis, 451
 - pelvic inflammatory disease, 455–458, 457b
 - pelvic pain, 603–606, 618–628
 - physical examination, 514–515
 - postpartum care, 715–716, 718–719t
 - postpartum mood and anxiety disorders, 727–730
 - pregnancy, 369, 683–689
 - sexual arousal disorders, 360
 - sexual assault, 304, 311, 318–324
 - sexual dysfunction, 355–357
 - sexually transmitted infections, 440–441
 - syphilis, 459–460
 - toxic shock syndrome, 425–426, 427t
 - trichomoniasis, 451–452, 452f
 - urethra, 479
 - urinary incontinence, 482–485, 484f, 485f
 - urinary tract infections, 471–472
 - vulvar cancers, 571–572
 - vulvovaginal candidiasis, 412–414, 414f

- breast cancer (*Continued*)
 incidence rates, 344
 inflammatory carcinoma, 348
 invasive, 345
 management, 347-348
 Paget disease, 345
 pathophysiology, 344-345
 physical examination, 345
 in pregnant women, 349
 prevention, 347
 screening, 156-157
- breast changes, in pregnancy, 677
- breast conditions, 337-352
 benign breast masses, 341-343
 cancer, 343-349
 mastalgia, 337-340
 nipple discharge, 340-341
- breast examination, 110-111
 inspection, 110
 lymph nodes, examination of, 110
 palpation, 110-111
- breastfeeding
 complications, 723-724
 effective counseling interventions, 78-80, 79t
 galactagogues, 723
Healthy People 2020, 720
 latch, 722-723
 milk supply, 723
 positioning, 720-722, 721-722t
- breast mass, 341-343
- bricoleur, in qualitative research, 62
- buboes, 450
- bupropion, 670
- BV. *See* bacterial vaginosis
- BWHBC. *See* Boston Women's Health Book Collective
-
- C**
- calcium
 after bariatric surgery, 167
 for menopause-related symptoms, 276b, 279
 for PMS, 504
- California Healthy Nail Salon Collaborative, 31
- California Pregnancy-Associated Mortality Review (CA-PAMR), 57
- cancer. *See also* breast cancer; cervical cancer; endometrial cancer; ovarian cancer; vulvar cancer
 colorectal, 157-158
 infertility and, 397
 menopause and, 275
 in midlife, 275
- Candida albicans*, 412
 nipple candidiasis, 724
- candidiasis, nipple, 724
- CA-PAMR. *See* California Pregnancy-Associated Mortality Review
- carbamazepine, 670
- cardiovascular disease
 counseling interventions for women, 80-81
 health, 184
 markers, 532
 menopause and, 274
 midlife and, 274
- cardiovascular system changes, in pregnancy, 679-680
- CBT. *See* cognitive-behavioral therapy
- CDC. *See* Centers for Disease Control and Prevention
- CD4 cells. *See* T-helper lymphocytes
- CD4 receptor, 464
- cefixime, 455, 455b
- celibacy, 213
- cell-mediated response, 697
- Centers for Disease Control and Prevention, 224, 685
 clinician resources, 331
 sexually transmitted infections testing, 324
 toxic shock syndrome, definition for, 427t
 use of contraception, 720
- cervical cancer, 186, 575-583
 assessment, 578-579
 clinical presentation, 577-578
 diagnostic testing, 578-580, 579t, 580t
 diethylstilbestrol, 577
 differential diagnoses, 580-581
 etiology and pathophysiology, 575-576, 576t
 further testing, 579-580
 genetic factors, 577
 genetic predisposition, 577
 high parity, 577
 history, 578
 HPV vaccines and, 581
 immunosuppression, 577
 incidence and prevalence, 575
 infectious agents and, 577
 management, 581-582
 nutrition and, 577
 patient counseling, 583
 pharmacologic therapy/treatment, 581-583
 physical examination, 578
 pregnancy and, 583
 prevention, 581
 referrals, 572
 risk factors, 576-577
 screening tests, 106-107, 155, 582
 sexual behavior, 577
 smoking, 577
 surgical treatment, 582
 therapeutic vaccines, 582-583
 treatment during pregnancy, 583
- cervical caps, 257-258, 257f
- cervical changes, in pregnancy, 678-679
- cervical cytology screening, 125-127, 155, 445
 conventional method, 125-126
 liquid-based methods, 126-127
- cervical effacement, 679
- cervical insufficiency, 705
- cervical polyps, 553-554

contraception (*Continued*)

- fertility awareness-based methods, 253–254, 254b
 - lactational amenorrhea method, 253
 - for postpartum women, 720
 - progestin hormonal methods
 - implants, 241–242, 241f
 - injection, 250–251
 - progestin-only pills, 249
 - progestin-only methods, 249–251
 - sterilization, 242
 - female, 242
 - male, 242
 - tubal occlusion, 242–243
 - vasectomy, 243
- contraceptive patch, 247–249, 248f
- copper IUD, 239–241, 239f
- corpus luteal cyst, 563
- counseling. *See* patient education and counseling
- cream, 406
- credibility, 63
- critical race theory, 20
- CRS. *See* congenital rubella syndrome
- cultural influences
 - chancroid, 540–541
 - hyperandrogenic disorders, 540
 - intimate partner violence, 306–307
 - pediculosis pubis, 451
 - pelvic pain, 615
 - qualitative research, 63
 - racism and health disparities, 21, 23t
 - sexual health, 228
 - sexually transmitted infections, 439
 - urinary incontinence, 491
 - urinary tract infections, 475
- culturally responsive care, 178–179b, 178–180
- cyclic changes, vagina, 97
- cystitis, 470, 472, 608t
- cystocele, 114f
- cytomegalovirus, 698
 - prenatal screening for, 698



DAA agents. *See* direct-acting antiviral agents

data analysis, 62

DCIS. *See* ductal carcinoma in situ

Deanow's model of development, 52–53

debulking, goal of, 593

decision-making

- evidence-based practice and, 58

- pregnancy and, 367–379

deep vein thrombosis, 727

dental care and hygiene, preconception care and, 664–665

dependability, 63

depot medroxyprogesterone acetate, 250–251, 499

depression

- menopause and, 272t, 276–278

- in midlife, 276–278

- postpartum, 729

- screening, 155

dermatoses, 547–553, 549b, 549t, 550–551t

desquamative inflammatory vaginitis, 417–419

- assessment, 417–418

- clinical presentation, 417

- differential diagnoses, 418

- etiology and pathophysiology, 417

- management, 418

- patient education, 418–419

detrusor, 480

developmental factors

- across life span, 39–49

- adolescence, 41–46

- early adulthood, 46–47

- midlife, 47–48

- older women, 48–49

DFSAs. *See* drug-facilitated sexual assault

DGI. *See* disseminated gonococcal infection

diabetes

- and preconception care, 666–667

- screening for, 160–162

Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), 316

Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR), 354

diagnostic testing

- bariatric surgery, 167

- breast cancer, 338t, 343t, 345–346

- cervical cancer, 578–580, 579t, 580t

- drug-facilitated sexual assault, 324

- hyperandrogenic disorders, 534–535

- infertility, 387–392

- mastalgia, 338–339, 338t

- pelvic pain, 605–606

- pregnancy, 324

- sexual dysfunction, 357

- sexually transmitted infections, 324

- uterine bleeding, 515–517, 516t

- vulvar cancer, 571

- vulvar skin disorders, 545, 545b

diaphragms, 256–257, 257f

diet and exercise

- counseling interventions for women, 80–81

- effective counseling for, 78, 79t

dietary supplements, 504

diethylstilbestrol, 577

differentiated-type vulvar intraepithelial neoplasia, 570

dilation and curettage, 586

direct-acting antiviral agents, 463

disabilities

- sexual abuse of women with, 327

- uterine bleeding and, 525–526

discrimination, 4b, 5

disseminated gonococcal infection, 454

diuretics, 505

DIV. *See* desquamative inflammatory vaginitis

diverticulitis, 608t

- episodic therapy, 448
- epistemology, 61
- EPT. *See* expedited partner therapy
- erectile dysfunction, 142–143
- Erikson's developmental model, 39–41, 40*t*
 Franz and White's adaptation of, 47*t*
- estimated date of birth, 683
- estrogen-androgen therapy, 286
- estrogen-bazedoxifene therapy, 286
- estrogen-progestogen therapy, 285–286
- estrogen therapy, 285, 286*t*, 421–422, 518
- ethical issues
 decision-making, 367–369
 infertility, 397–398
 pregnancy diagnosis, 368*b*
 pregnancy discovery, 367–369
 resolution process, 367–369
- ethinyl estradiol, 247
- ethnographer's goal, 63
- etiology and
 pathophysiology, 569–570
 breast cancer, 344–345, 344*b*
 cervical cancer, 575–576, 576*t*
 endometrial cancer, 584
 hyperandrogenic disorders, 529–530
 infertility, 385–386
 mastalgia, 337, 338*t*
 menstrual-cycle pain and premenstrual conditions, 500–501
 ovarian cancer, 589–590
 pelvic pain, 602–603
 sexual dysfunction, 354–355
 of urinary incontinence, 479–482, 480*f*
 urinary tract infections, 469
 vulvar cancers, 569–570
- evening primrose oil, 504
- evidence-based management, 57
- evidence-based practice, 55
 barriers to, 66–67
 best practices from best evidence, 66
 in clinical practice, 66–67
 decision-making and, 58, 58*t*
 defined, 55
 dimensions of, 58
 feminist perspective on, 55–56
 history of, 55–58
 qualitative research, 61–63
 quality perspective on, 55–56
 quantitative research, 59–61
 research methods, 58*t*, 59–66
 types of research evidence, 59, 60*t*
- evidentiary collection. *See* evidentiary examination
- evidentiary examination, 302
 body samples, 323–324
 hair samples, 323
 kit, 323, 323*f*
 known sample, 323
 swabs and smears, 23
- EVUS. *See* endovaginal ultrasound
- exercises, 78
 counseling, 78
 menopause and, 278–279
 postpartum period, 716
 preconception care and, 660
- exogenous gonadotropins, 394
- expedited partner therapy, 453
- external genitalia
 anatomy and physiology, 90–93, 90*f*
 pelvic examination, 113–115
- extragenital lesions, 447
-
- FAB contraception. *See* fertility awareness-based contraception
- fallopian tubes, 92
 mobility, 97
- falls in older adults, 78–79
- family health history
 cervical cancer, 585–586
 health history, 104
 infertility, 386–387
 menstrual-cycle pain and premenstrual conditions and, 496
- family involvement, in postpartum care, 716
- female ejaculation, 216–217
- female genital cutting, 106, 107*b*, 107*f*
- Female Pelvic Pain Questionnaire, 629–645
- female sexuality, 211–233
- FemCap, 257, 257*f*
- feminism, 4*b*, 39
 defined, 3
- feminist model, 5–6
- feminist perspective, 3–10
 components of, 4*b*
 on evidence-based practice, 55–56
 gynecologic health and, 3, 10
 model of care based on, 5–6
 principles of, 55–56
 strategies for analysis of women's health, 7–110, 7*t*
- feminist theories, 40–41
- fertility awareness-based contraception, 253–254, 254*b*
- fertilization and implantation process, 385
- fetal genetic screening, 691–692
- fetal heart tones, 688
- fibroids. *See* uterine fibroids
- financial barriers, 182
- first-trimester bleeding, 692–693
- first-trimester complications, of pregnancy, 702–705
 ectopic pregnancy, 703–704, 704*b*
 hydatidiform mole, 704–705, 704*f*
 hyperemesis gravidarum, 702–703
 spontaneous abortion, 703, 703*t*
- Fishbein–Aizen Theory of Reasoned Action, 65
- Five P's of Sexual Health, 440, 440*b*
- fluconazole, 416
- fluid intake and urinary incontinence, 481, 490
- fluorescent treponemal antibody absorbed (FTA-ABS) test, 460

gynecologic infections, 401–432
 bacterial vaginosis, 403–412
 Bartholin cyst and abscess, 427–429
 genital piercing, 429–432
 toxic shock syndrome, 425–426
 vaginal health, maintenance of, 401, 402*t*
 vulvovaginal candidiasis, 404*t*, 412–417, 413*f*, 414*f*

II

habitual preventive emptying, 487
Haemophilus ducreyi, 450
 HBsAg. *See* hepatitis B surface antigen
 health, 6
 biomedical model definition of, 6–7
 defined, 77
 social model definition of, 6–7
 Health and Human Services Department (U.S.), 75
 healthcare systems and infrastructure, 189–190
 health disparities. *See* racism and health disparities
 health history, 99–124
 abnormal symptoms, 107
 allergies, 104
 bariatric surgery, 166–167
 cervical cancer screening, 106–107
 contraceptive use, 105
 douching, 106
 endometrial cancer, 585–586
 family health history, 104
 gynecologic history, 99–124
 hyperandrogenic disorders, 533
 infertility, 386–387
 intimate partner violence, 299–302, 313
 medications, 104
 menstrual history, 104–105
 mental health history, 104
 occupational history, 104
 pelvic infections, 106
 pelvic pain, 604–605
 personal habits, 105
 pregnancies, 105, 106*b*, 683–688
 rectal health, 106
 safety issues, 104–105
 sexual assault, 319–320, 320*b*
 sexual dysfunction, 355–357
 sexuality and sexual health, 105, 222–224
 social history, 104
 substance abuse, 104
 surgical procedures, 103–104
 urinary tract infections, 471
 urologic health, 106
 uterine bleeding, 513–514, 514*t*
 vaginal infections, 106
 vulvar skin disorders, 544
 Health Insurance Portability and Accountability Act, 319
 health maintenance screening, 149–162, 152–154*t*
 health problems, prevention of, 569
 health promotion, 75–85

counseling and, 77
 definitions, 75
 education and, 78
 health, defined, 77
 immunization guidelines, 82–85, 84*t*
 as national initiative, 75–77, 76*b*
 prevention, defined, 77–78
 strategies, 504
 tobacco use, 81–82
 weight loss, 82
Healthy People 2000: National Health Promotion and Disease Prevention Objectives, 75
Healthy People 2010, 75
Healthy People 2020, 75–78, 76*b*, 720
 Hegar's sign, 677
 HELLP syndrome, 709
 hematologic changes, in pregnancy, 679–680
 hemorrhage, postpartum, 709
 hemorrhagic cyst, ovarian, 563
 hemostasis, 713
 hepatitis A, preconception care and, 663*t*, 664
 hepatitis B, 160, 461–462, 701
 assessment, 462
 differential diagnoses, 462
 management, 462
 patient education, 462
 preconception care and, 663*t*, 664
 pregnancy, 462
 prevention, 462
 serologic tests, 461*t*
 hepatitis B surface antigen, 461
 hepatitis C, 462–463
 assessment, 463
 differential diagnoses, 463
 management, 463
 patient education, 463
 pregnancy, 463
 prevention, 463
 virus infection, screening for, 158
 women with HIV infection, 463
 herbal remedies
 menopause, 288–290*t*
 menstrual-cycle pain and premenstrual conditions, 504
 hermaphroditism, 97
 herpes simplex virus, 140–141, 446, 702
 types of, 446–447
 Herpesviridae, 698
 heteronormativity, 176
 heterosexism, 177, 181
 hidradenitis suppurativa, 546–547
 HIPAA. *See* Health Insurance Portability and Accountability Act
 hirsutism, 530
 historical trauma, 177
 history. *See* health history
 HIV. *See* human immunodeficiency virus
 homeopathy, 497
 homophobia, 4*b*, 177, 181
 hormonal contraception, 243–251

- infant, birth defects in, 699
- infections. *See* gynecologic infections
- infectious disease
- pregnancy and, 685–686, 685*t*
- infertility, 383–398
- adoption options, 396
 - anatomy and physiology related to, 384
 - assessment, 386–392
 - assisted reproductive technologies, 395
 - best practices for care, 396
 - cancer and, 397
 - definitions, 383–384
 - diagnostic testing, 387–392
 - differential diagnoses, 392
 - ethical issues, 397–398
 - etiology, 385–386
 - family considerations, 397
 - fertilization and implantation process, 385
 - history, 386–387
 - hyperandrogenic disorders, 531
 - hysterosalpingogram, 391
 - hysteroscopy, 391
 - laboratory testing, 389–390
 - laparoscopy, 391
 - management, 392–396
 - options for, 396
 - ovulation detection, 387–388
 - ovulation induction, 392–394
 - pathophysiology, 385–386
 - patient education and counseling, 392
 - physical examination, 387
 - prevention of, 392
 - psychological considerations, 397
 - relationship considerations, 397
 - semen analysis, 388–389, 389*t*
 - short luteal phase treatment, 394–395
 - social considerations, 397
 - third-party reproduction, 395–396
 - transvaginal ultrasound, 391
 - treatment of, 539
 - unexplained, 386
- inflammatory carcinoma of the breast, 345
- influenza, preconception care and, 663*t*, 664
- insulin resistance, 532
- insulin sensitizing agents, 538
- integumentary system changes, in pregnancy, 679
- internal genitalia
- fallopian tubes, 92
 - ovaries, 91–92
 - urethra, 91
 - uterus, 92–93, 92*f*
 - vagina, 93
- International Association of Forensic Nurses, 331
- International Consultation on Incontinence, 486
- International Pelvic Pain Society, 646–656
- International Society for Premenstrual Disorders, 500
- intersectionality, 4*b*, 5, 13–14
- intersex, 97–98, 175
- intestinal obstruction, 608*t*
- intimate partner violence, 180, 295–311
- abrasion, 302
 - adolescents, 305
 - blunt force injuries, 302
 - chronic health conditions and, 298
 - clinical presentation, 297–299
 - cultural awareness, 306–307
 - cultural influences, 306–307
 - cycles of, 296–297
 - definitions, 295
 - documentation, 303
 - ecchymosis, 302
 - elderly women, 306
 - epidemiology, 297
 - gastrointestinal system, 298
 - hematoma, 302
 - history, 299
 - impacts of, 297
 - laceration, 302
 - management of, 303–304
 - mental health and, 298
 - neurologic system, 298
 - older women, 306
 - petechiae, 302
 - physical examination, 302
 - pregnant women, 305–306
 - prevention, 307
 - reproductive health, 298
 - risk factors, 297
 - screening for, 156, 299–302, 300*b*
 - sharp force injuries, 302–303
 - special population, 305–307
 - strangulation, 304–305, 304*b*
 - substance abuse and, 298
 - teens, 305
 - theories of, 296–297, 310*f*
 - types of, 295–296
 - women with disabilities, 306
- intracytoplasmic sperm injection, 389
- intrauterine contraception, 168, 239–241, 239*f*, 240*f*
- intrauterine device, 239–241
- advantages and disadvantages, 241
 - noncontraceptive benefits, 241
 - safety, 240
 - side effects, 240–241
 - women using, 457–458
- invasive breast cancer, 345
- Iowa Model of EBP to Improve the Quality of Care, 64*t*
- IPV. *See* intimate partner violence
- irritable bowel syndrome, 608*t*, 610
- irritant contact dermatitis, 547–548, 549*t*
- isoflavones, 290, 291
- ISPM. *See* International Society for Premenstrual Disorders
- IUC. *See* intrauterine contraception
- IUD. *See* intrauterine device

male sexual and reproductive health (*Continued*)

- erectile dysfunction, 142–143
- premature ejaculation, 141–142, 142*b*
- gay and bisexual, 144–145
 - healthcare access and experiences, 144–145
 - health disparities, 145
 - HIV, 145
 - syphilis, 145
- hypothalamic–pituitary–gonadal axis, 135, 136*f*
- sexually transmitted infections, 138–141
 - chlamydia, 138
 - epididymitis, 140
 - gonorrhea, 138–139
 - HPV, 140–141
 - nongonococcal urethritis, 139–140
 - syphilis, 140, 141*t*
- spermatogenesis, 135
- testicular cancer, 144
- male sterilization, 242
- management
 - amenorrhea, 524–525, 525*t*
 - atrophic vaginitis, 420–425
 - bacterial vaginosis, 406, 407–408*t*, 408–410, 409*f*
 - bariatric surgery, 167–168
 - Bartholin cyst and abscess, 428–429
 - breast cancer, 343
 - cervical cancer, 581–582
 - chancroid, 450
 - chlamydia, 453
 - combined oral contraceptives, 521
 - complementary and alternative methods, 408–409
 - desquamative inflammatory vaginitis, 418
 - dyspareunia, 363
 - endometrial cancer, 586–588
 - genetic and epigenetic changes, 573–574
 - genital herpes, 448–449, 449*t*
 - genital piercing, 431
 - gonorrhea, 455, 455*b*
 - gynecologic cancers, 572–573
 - hepatitis B, 462
 - hepatitis C, 463
 - human immunodeficiency virus, 465
 - human papillomavirus, 445–446, 446*t*
 - hyperandrogenic disorders, 535
 - infertility, 392–396
 - of intimate partner violence, 303–304
 - laser treatment, 573
 - mastalgia, 339–340
 - menstrual-cycle pain and premenstrual conditions, 497–499
 - ovarian cancer, 593–595
 - pediculosis pubis, 451
 - pelvic inflammatory disease, 457, 458*t*
 - pelvic pain, 611–614
 - pregnancy, 689–692
 - sexual arousal disorders, 360–361
 - sexual violence, 304
 - syphilis, 460
 - toxic shock syndrome, 426–427
 - trichomoniasis, 452
 - urinary incontinence, 486–490
 - urinary tract infections, 472–475, 473*t*
 - uterine bleeding, 520–524, 521*t*, 522*b*, 523*f*, 523*t*
 - vulvar cancers, 572–573, 573*t*
 - vulvovaginal candidiasis, 407–410*t*, 414–416
 - women's orgasmic disorder, 362
 - women's sexual interest/arousal disorder, 357–361
- marsupialization, 429
- mastalgia, 337–340
 - assessment, 338–339
 - clinical presentation, 338
 - diagnostic testing, 338–339, 338*t*
 - differential diagnoses, 339
 - etiology and pathophysiology, 337
 - management, 339–340
 - nonpharmacologic therapies, 339
 - pharmacologic therapies, 339
 - physical examination, 338
- mastitis, 723–724
- mature cystic teratomas, 563
- mechanical hair removal, 537
- medical diagnoses, 224–225
- medical forensic history, 319–320, 320*b*
- medical history
 - general, 103–104
 - gynecologic, 102*b*
 - normal and abnormal uterine bleeding, 514
 - pregnancy, 684–686
- medicalization, 4*b*, 6
 - of menopause, 267–291, 268*t*, 269*b*
- medication abortion, 375–376
- Mediterranean diet, 658
- member checking, 63
- men
 - condoms for, 254–255, 255*f*
 - etiology of infertility, 386
 - semen analysis, 388–389, 389*t*
 - sterilization for, 242
 - treatment for infertility, 395
- menopause, 267–291
 - acupuncture for, 291
 - cancer and, 275
 - cardiovascular disease and, 274
 - causes, 270
 - clothing for, 280
 - complementary and alternative medicine for, 287–291
 - depression and, 272*t*, 276–278
 - diabetes and, 274
 - dietary management of, 278
 - differential diagnoses, 272, 272*t*
 - environmental management of, 280
 - ethnicity of, 270, 274
 - exercise and, 278–279
 - herbal remedies, 288–290*t*
 - isoflavones and, 290, 291
 - lifestyle approaches for symptom management, 278–281
 - medicalization of, 267–268, 268*t*, 269*b*

- Nägele's rule, 683, 684b
- National Alliance to End Sexual Violence, 331
- National Cancer Institute, 344
- National Center for the Prosecution of Violence Against Women, 331
- National College Health Assessment, 187
- National Health and Nutrition Examination Surveys, 184
- National Institutes of Health's Revitalization Act of 1993, 7
- National Intimate Partner and Sexual Violence Survey, 313
- National LGBT Health Education Center, 179
- National Notifiable Diseases Surveillance System, 442
- National Organization of Nurse Practitioner Faculties, 368b
- National Osteoporosis Foundation, 276
- A National Protocol for Sexual Assault Medical Forensic Examinations: Adults/Adolescents*, 318
- National Sexual Violence Resource Center, 331
- natural menopause, 268–270, 270b
- natural vs. bioidentical hormones, 286–287
- NCPVAW. *See* National Center for the Prosecution of Violence Against Women
- Neisseria gonorrhoeae*, 128–129, 454, 455, 701
- neurodevelopment, adolescence, 43–44
- neurogenic detrusor, 480
- neurologic system, 298
- changes, in pregnancy, 681
- neuropathic pain, 602
- nipple candidiasis, 724
- nipple discharge
- assessment, 340–341
- diagnostic testing, 341
- differential diagnoses, 341
- management, 341
- physical examination, 340–341
- NIPT. *See* noninvasive prenatal testing
- NISVS. *See* National Intimate Partner and Sexual Violence Survey
- NNDSS. *See* National Notifiable Diseases Surveillance System
- nociceptive pain, 602
- NOF. *See* National Osteoporosis Foundation
- noncontact unwanted sexual experiences, 314b
- nonexperimental research, 59
- nongonococcal urethritis, 139–140
- nonhormonal contraception, 236
- nonhormonal medications for menorrhagia, 522b
- noninvasive prenatal testing, 692
- nonlatex condoms, 255
- nonoccupational postexposure prophylaxis, 326
- nonpharmacologic management and treatment
- for dysmenorrhea, 497–498
- for mastalgia, 339
- for PCOS, 535–537
- for pelvic pain, 611–612
- for premenstrual-cycle syndrome and dysphoric disorder, 504
- for urinary incontinence, 487–489
- nonsexual transmission, 451
- nonsteroidal anti-inflammatory drugs, 498
- normal menses, physiology and patterns of, 519
- normal uterine bleeding, 511–513, 512f
- NSAIDs. *See* nonsteroidal anti-inflammatory drugs
- NSVRC. *See* National Sexual Violence Resource Center
- nucleic acid amplification tests, 324, 452, 455
- nutrition
- cervical cancer and, 577
- menopause and, 279
- menstrual-cycle pain and premenstrual conditions, 501
- and preconception care, 657–658
- nutritional therapy, 706
-
- obesity, 165
- and preconception care, 665–666
- occupational history, 104
- OCPs. *See* oral contraceptive pills
- OHSS. *See* ovarian hyperstimulation syndrome
- “OLD CAARTS,” pain history, 604
- older adulthood/women
- biology of, 48
- clinical application, 49
- intimate partner violence, 306
- lesbian, bisexual, queer, and transgender health, 200
- physiology of, 48
- psychosocial development, 48–49
- screening for, 156–159
- sexual health, 227–228
- sexually transmitted infection in, 443–444
- urinary tract infections, 475
- uterine bleeding, 526, 526b
- oligohydramnios, 708
- oppression, 3, 4b, 13–14
- oral contraceptive pills, 186, 438, 498, 537, 577
- orgasmic disorder, 361–362
- assessment, 361–362
- management, 362
- ospemifene, 422
- osteoporosis
- menopause and, 275–276, 275t
- in midlife, 275–276, 275t
- screening, 159
- ovarian cancer, 186, 589–598
- assessment, 591–592
- clinical presentation, 591, 591t
- description of, 589
- diagnostic testing, 592
- differential diagnoses, 592
- emerging evidence, 595
- etiology and pathophysiology, 589–590
- follow-up care, 595–596
- management, 593–595
- patient education, 595–596
- postoperative treatment, 595–596
- prevention, 592–593
- referrals, 593
- risk factors, 589–590, 590
- screening, 159, 593

- pelvic inflammatory disease, 455–458, 601, 607t
 assessment, 456, 457b
 differential diagnoses, 456
 management, 457, 458t
 patient education, 457
 pregnancy, 457
 prevention, 456
 treatment of, 458t
- pelvic muscles, strength in, 219–220
- pelvic organ prolapse, 114
- pelvic pain, 456, 601–615
 adolescents, 614
 assessment, 603–606, 618–628
 causes of, 609–611, 609t
 clinical presentation, 603
 complementary and alternative treatments, 613
 cultural influences, 615
 diagnostic imaging, 605–606
 differential diagnoses, 606–609t, 606–610
 etiology and pathophysiology, 602–603
 Female Pelvic Pain Questionnaire, 629–645
 gender and, 615
 history, 604–605
 incidence rates, 602
 irritable bowel syndrome, 610
 management, 611–614
 musculoskeletal causes, 611
 older women and, 614
 ovarian hyperstimulation syndrome, 609
 ovarian remnant syndrome, 609t, 610
 ovarian retention syndrome, 609t, 610
 patient education, 614
 pelvic adhesions, 609
 pelvic congestion syndrome, 610
 perimenopause and, 614
 physical examination, 605
 scope of problem, 602
 transgender and, 615
 urologic causes, 611
- pelvic pathology, 496
- pelvic support, 87–89, 88f, 89f
- penis, 134–135
- perimenopause, 526, 539, 614
- periurethral glands, 91
- Pew Research Center (2013) survey, 180
- pharmacokinetic profile, 248
- pharmacologic management and treatment
 for acute non-life-threatening heavy menstrual bleeding, 520–522, 521b, 521t
 for cervical cancer, 581–582
 for dysmenorrhea, 498–499
 for generalized anxiety disorder, 729
 for hidradenitis suppurativa, 546
 for hyperandrogenic disorders, 537–538
 for mastalgia, 339
 for menopause, 281–287
 for menstrual-cycle pain and premenstrual conditions, 498–499
- nonhormonal, for acute heavy menstrual bleeding, 522, 522b
 for ovarian cancer, 593–595
 for pelvic pain, 612
 for postmenopausal osteoporosis, 281–274t
 for sexually transmitted infections, 325–326
 for urinary incontinence, 489
 for vulvar cancers, 572–573
- phenomenology, 62
- photo documentation, intimate partner violence and, 303
- photographic evidence, 303
- phthalates, 222
- Phthirus pubis*, 451
- physical examination
 bariatric surgery, 167
 breast, 110–111
 breast cancer, 345
 cervical cancer, 578
 endometrial cancer, 585–586
 gynecologic visit, 108–125
 hyperandrogenic disorders, 533–534
 infertility, 387
 intimate partner violence, 297–299
 male sexual and reproductive health, 137–138
 mastalgia, 338
 pelvic examination, 111–125
 pelvic pain, 605
 pregnancy, 688, 689f
 sexual dysfunction, 357
 sexuality and sexual health, 224
 sexually transmitted infections, 440–441
 urinary tract infections, 471
 uterine bleeding, 514–515
 vulvar skin disorders, 544–545
- physical violence, 295
- PID. *See* pelvic inflammatory disease
- pituitary gland, 95
- pituitary system, 714–715
- PK profile. *See* pharmacokinetic profile
- placenta accreta, 709–710, 710f
- placenta previa, 709
- PMAD. *See* postpartum mood and anxiety disorders
- PMDD. *See* premenstrual dysphoric disorder
- PMS. *See* premenstrual syndrome
- Pneumocystis jiroveci*, 463
- pneumonia, 699
- poly ADP-ribose polymerase, 595
- polyarthropathy syndrome, 698
- polycystic ovarian syndrome, 185, 514, 518, 531
 biochemical features of, 530
 diagnosis of, 535, 536t
 management, 535, 537–538
 phenotypes, 535b
 and preconception care, 667
- polyhydramnios, 708
- polymerase chain reaction, 448
- POP. *See* pelvic organ prolapse
- POPs. *See* progestin-only pills
- postoperative treatment, ovarian cancer, 595–596

- preconception care (*Continued*)
- sexually transmitted infections, 665
 - stress management, 660
 - substance use, 661
 - TDAP, 663t, 664
 - thyroid disease, 667–668
 - tobacco and nicotine, 661–662
 - varicella, 663t, 664
 - Zika virus, 665
- preeclampsia, 708–709, 727
- pre-exposure prophylaxis, 465
- pregnancy
- anatomy and physiologic adaptations of, 677–681, 678t
 - bacterial vaginosis and, 411
 - bariatric surgery and, 167–169, 169t, 170t
 - breast cancer and, 349
 - breast changes, 677
 - cardiovascular system changes, 679–680
 - cervical cancer and, 583
 - chancroid, 450
 - chemical exposure and, 687–688
 - chlamydia, 454
 - common discomforts, 690–691
 - complications of
 - cytomegalovirus, 698
 - diagnosis of, 697–702
 - first trimester complications of, 702–705
 - group B *Streptococcus*, 700
 - hypertensive disorders of, 708–709
 - late-pregnancy bleeding, 709–710
 - parvovirus B19, 698
 - rubella (German measles), 699
 - second trimester complications of, 705–708
 - sexually transmitted infections, 700–702
 - third-trimester complications of, 708–710
 - toxoplasmosis, 698–699
 - urinary tract infection, 697
 - varicella-zoster virus, 699–700
 - Zika virus, 700
 - decision making, 367–369
 - diagnosis of, 683–694
 - discovery, 367–369
 - early pregnancy loss, 692–693
 - ectopic, 693
 - endocrine system changes, 681
 - environmental history, 687b
 - first-trimester bleeding, 692–693
 - gastrointestinal changes, 679
 - genetic screening, 686, 686b, 691–692
 - genital herpes, 450
 - gonorrhea, 455
 - health history, 105
 - hematologic changes, 679–680
 - hepatitis B, 461
 - hepatitis C, 461
 - human immunodeficiency virus, 465–466
 - hyperandrogenic disorders, 539
 - infectious disease history and, 684–686, 685t
 - integumentary system changes, 679
 - intention, 367, 378–379
 - intimate partner violence, 307
 - laboratory testing, 688–689, 689b
 - laboratory value changes in, 680t
 - management, 689–692
 - medical history, 684–686
 - menstrual-cycle pain and premenstrual conditions, 506
 - menstrual history, 683–684, 684b
 - musculoskeletal system changes, 681
 - neurologic system changes, 681
 - patient education, 689–690, 690b, 690t
 - pediculosis pubis, 451
 - pelvic inflammatory disease, 457
 - physical examination, 688, 689f
 - and postpartum women, 226–227
 - prenatal care referral, 693–694
 - prevention, 326
 - prior obstetrical history, 684
 - psychosocial changes, 681
 - renal system changes, 680–681
 - reproductive system changes, 677–679
 - resolution, 367–369
 - resolving, 371–372
 - respiratory system changes, 680
 - risk assessment, 683–689
 - sexually transmitted infections, 444
 - sexual violence and, 305–306, 316
 - substance use and abuse history and, 686
 - syphilis, 461
 - test, 324
 - trichomoniasis, 452–453
 - urinary incontinence and, 481, 482
 - urinary tract infections, 475
 - vital sign changes in, 680t
 - vulvovaginal candidiasis and, 416
- pregnancy diagnosis, decision-making and
- resolution, 367–379
 - abortion options, 372–377
 - adolescents, 378
 - adoption options, 371–372
 - assessment, 369
 - competent caring for women with, 367–369
 - pregnancy options counseling, 369–371
 - professional responsibilities, 367–369, 368b
 - resolving pregnancy, options for women with, 371–372
 - values clarification, 369, 370t
- premature ejaculation, 141–142, 142b
- premature rupture of membranes, 705–706
- premenstrual dysphoric disorder, 499–507, 502t
- assessment, 501, 502t
 - diagnostic criteria for, 503
 - differential diagnoses, 503
 - etiology of, 500–501
 - health-promoting strategies, 504
 - incidence, 500
 - nonpharmacologic therapies, 504
 - overview, 499–500
 - pharmacologic therapies, 504–505
 - symptoms of, 502t

- radiation therapy, 588
 RAINN. *See* Rape, Abuse, and Incest National Network
 rape. *See* sexual assault
 Rape, Abuse, and Incest National Network, 331
 rapid plasmin regain test, for syphilis, 160
 rectocele, 114*f*
 rectovaginal examination, 122–123, 123*f*
 relationship factors, infertility, 397
 renal system, 715
 changes, in pregnancy, 680–681
 reproductive system changes, in pregnancy, 677–679. *See also*
 male sexual and reproductive health
 cervical changes, 678–679
 pelvic floor changes, 679
 uterine changes, 677–678, 678*f*
 vaginal and vulvar changes, 679
 research
 and clinical decision making, 58
 critiquing research studies, 67, 68*t*
 evidence
 sources of, 71*t*
 types of, 59
 evidence-based practice and, 58*t*, 59
 finding, 67
 methods, 59–66, 60*t*
 qualitative research, 61–63
 quantitative research, 59–61
 studies, 67, 68*b*
 transitional research, 64–65*t*, 64–66
 respiratory system changes, in pregnancy, 680
 reverse bladder retraining, 487
 risky sexual behavior, counseling intervention for women, 81
 roux-en-Y gastric bypass, 165
 rubella (German measles), 699
 rubella immunity, 156
 ruptured ectopic pregnancy, 704
 RYGB. *See* roux-en-Y gastric bypass
-
-
- SAB. *See* spontaneous abortion
 SAFE. *See* Sexual Assault Forensic Examiner
 safety
 of abortion, 376–377
 combined oral contraceptives and, 245–247
 health history, 104–105
 intrauterine device, 240
 motor vehicle counseling, 80
 of pregnancy, 688
 sexual assault and, 326
 SANE. *See* Sexual Assault Nurse Examiner
 screening
 for adolescents, 151
 alcohol misuse, 151–155
 breast cancer, 156–157
 cervical cancer, 155
 chlamydia, 128–129, 155
 cholesterol levels, 159
 colorectal cancer, 157–158
 for cytomegalovirus, 698
 depression, 155
 endometrial cancer, 586
 genetic, 686, 686*b*, 691–692
 health maintenance, 149–162, 152–154*t*
 height, 155
 hepatitis C virus infection, 158
 human immunodeficiency virus infection, 156
 hypertension, 156
 intimate partner violence, 156, 299–302, 300*b*
 lipid disorders, 158
 Neisseria gonorrhoeae, 128–129
 for older women, 156–159
 osteoporosis, 159
 ovarian cancer, 159, 593
 recommendations, comparison of, 152–154*t*
 rubella immunity, 156
 sexually transmitted infections, 440, 440*b*, 441*b*
 tobacco use, 156
 for toxoplasmosis, 698–699
 type 2 diabetes, 160–162
 for varicella, 699–700
 weight, 155
 scrotum, anatomy of, 133
 SDM. *See* Standard Days Method
 seated breast palpation, 111
 secondary dysmenorrhea, 496
 secondary postpartum hemorrhage, 726
 secondary syphilis, 458, 459*t*
 second-trimester complications, of pregnancy, 705–708
 amniotic fluid, 708
 cervical insufficiency, 705
 gestational diabetes, 706
 preterm labor and birth, 705–706
 secretory phase, 96–97
 selective serotonin reuptake inhibitors, 504–505, 729
 semen analysis, 388–389, 389*t*
 seminal vesicles, anatomy of, 134
 serial monogamy, 213
 serous/mucinous cystadenomas, 563
 SES. *See* socioeconomic status
 sex/gender, 4, 4*b*, 173, 175
 sexism, 4*b*
 sexual abuse, 439
 sexual agency, 218–219
 sexual anatomy and physiology, 216–217
 sexual arousal disorders, 215, 360–361
 assessment, 360
 management, 360–361
 sexual assault, 295, 313–333. *See also* intimate
 partner violence
 acute traumatic injury, 314–315
 advocacy services, 326
 age of victims, 326–327
 assessment, 300
 behavioral reactions to, 316
 clinician resources, 331
 cultural values and beliefs, 327
 definitions, 295, 313

- sexual response, 353–354
 in women, 217–218, 219b
- sexual rights, 212b
- sexual self-knowledge, 215–218
 anatomy and physiology, 216–217
 definition, 215
 genital sexual arousal, 215
 response, 217–218, 219b
- sexual violence. *See* sexual assault
- sharp force injuries, IPV and, 302–303
- short luteal phase treatment, 394–395
- Skene glands, 454
- skin cancer, 79t, 80
 effective counseling for, 80
- skin-to-skin contact, 716
- sleep and menopause, 280–281
- sleeve gastrectomy, 165
- social construction, 4, 4b
- social model of health, 6–7
- sociocultural factors
 health history, 104
 infertility, 397
- socioeconomic status, 4b
- somatic pain, 602
- sonohysterosalpingography, 390–391
- speculum examination, 115–119, 116f, 117f
- sperm, 388–389, 389t
- spermatogenesis, 135
- spermicides, 255–256
- spontaneous abortion, 703
 types of, 703t
- spontaneous rupture of membranes, 706
- SROM. *See* spontaneous rupture of membranes
- SSRIs. *See* selective serotonin reuptake inhibitors
- staging of ovarian cancer, 594t
- Standard Days Method, 253
- Staphylococcus aureus*, 425
- sterilization, 242
 female, 242
 male, 242
- Stetler model, conceptual adaptation, 65t
- STIs. *See* sexually transmitted infections
- STOP Violence Against Women Formula Grant Program, 319
- strangulation, 304–305, 304b
- Streptococcus pyogenes*, 425
- stress management for menopause, 280
- stress urinary incontinence, 488b
- stretch marks, 679
- structural discrimination, 5
- styrene ethylene butylene styrene, 255
- substance abuse, 184
 health history, 104
 intimate partner violence, 298
 pregnancy and, 686
 sexual assault and, 298, 318
 sexually transmitted infections and, 439–440
 sexual violence and, 298, 318
- SUI. *See* stress urinary incontinence
- supine breast palpation, 110–111
- surgical lysis of adhesions, 609
- surgical treatment, pelvic pain, 612–613
- symptothermal method, 254
- syncope, 445
- synthetic androgenic hormones, 560t
- syphilis, 140, 141t, 160, 458–461, 701
 assessment, 459–460
 differential diagnoses, 460
 gay and bisexual health and, 145
 management, 460
 patient education, 460–461
 pregnancy, 461
 prevention, 460
 stages of, 459t
 treatment of, 460, 460t
- systematic review, 61
- systemic antiviral therapy, 448
- systemic vascular resistance, 679

 T

- Tanner scale, 42, 42f
- TENS. *See* transcutaneous electrical nerve stimulation
- testes, anatomy of, 133
- testicular cancer, 144
- T-helper lymphocytes, 464
- therapist referrals, 363–364
- third-party reproduction, 395–396
- thrombophilias, 668
- thyroid disease
 menopause and, 276
 in midlife, 276
 and preconception care, 667–668
- thyroiditis, 727
- thyroid-stimulating hormone, 605
- thyrotoxicosis, 727
- tinidazole, 452
- tobacco use
 cervical cancer and, 577
 health promotion, 81–82
 menopause and, 270
 patient education and counseling, 81–82
 preconception care and, 661–662
 screening, 156
- topical antiviral therapy, 448
- topical preparations, 538
- toxic shock syndrome, 425–427
 adolescents, 427
 assessment, 425–426, 427t
 clinical presentation, 425
 description, 425
 differential diagnoses, 426
 emerging evidence, 427
 etiology and pathophysiology, 425
 incidence, prevalence, and scope, 425
 management, 426–427
 patient education, 427
 prevention, 426
- Toxoplasma gondii*, 698

- U.S. Preventive Services Task Force, 152–154t, 728
 USPSTF. *See* U.S. Preventive Services Task Force
 uterine artery embolization, 523–524, 557
 uterine bleeding, 511–528
 abnormal, 513
 adolescents, 525
 amenorrhea, 519
 anovulatory, 518–519, 518t
 diagnosis and management of amenorrhea, 524–525
 diagnostic testing, 515–517, 516t
 differential diagnosis, 517–520
 disabilities and, 525–526
 health history, 513–514, 514t
 laboratory testing, 515–517, 516t
 management, 520–524, 521b, 521t, 522b, 523f, 523t
 menorrhagia, 516
 normal menses, 519
 older women, 526, 526b
 perimenopause and, 526
 pharmacologic management of, 520–522, 521b, 521t
 physical examination, 514–515
 special considerations, 525–526
 uterine changes, 677–678, 678f
 uterine fibroids, 517, 554–558, 556t, 607t
 uterine infection, 725
 uterine position, 120–121f
 uterine subinvolution, 725–726
 uterus
 anatomy, 92–93, 92f
 menstrual cycle and, 95
 system, 713
 UTIs. *See* urinary tract infections
 U visa, 327
-
- V
- vaccinations. *See also* immunizations
 booster, 462
 health promotion, 82–85, 84t
 human papillomavirus, 445, 581
 vagina
 anatomy, 93
 infection history, 106
 lubricants and moisturizers for menopause, 279–280, 279t
 menstrual cycle and, 97
 pelvic examination, 113–115
 vaginal bleeding, 703–705, 710
 vaginal changes, in pregnancy, 679
 vaginal discharge, 452
 vaginal estrogen, 489
 vaginal infections, 185
 vaginal lesions, 444
 vaginal microbiome, 401–403
 life-cycle changes in, 401–102
 vaginal ring, 247–249, 248f
 vaginal secretions, 401–402
 sample preparation for microscopic examination, 130
 vaginal sponges, 258–259, 258f
 vaginal system, 713–714
 vaginitis and vaginosis, 403
 atrophic vaginitis, 419–425
 bacterial vaginosis, 403–412
 desquamative inflammatory vaginitis, 417–419
 prevention, 403
 vulvovaginal candidiasis, 412–417
 valproate, 670
 Valsalva maneuver, 456, 488b
 varicella-zoster virus, 699–700
 “vascular aging,” 184
 vas deferens, anatomy of, 134
 vasectomy, 143–144, 243
 VDRL. *See* Venereal Disease Research Laboratory
 venereal disease, 437
 Venereal Disease Research Laboratory, 160, 441, 460
 venous thromboembolism, 244, 726–727
 vibrators, sexual health, 221–222
 virilization, 531
 virologic cure, 463
 visceral pain, 602
 vitamins and supplements
 for menopause, 279
 for menstrual-cycle pain and premenstrual conditions, 498
 voiding diary, 482–483, 484f
 VTE. *See* venous thromboembolism
 vulva, anatomy of, 90–91, 90f
 vulva conditions. *See* vulva skin conditions
 vulvar cancer, 569–575
 assessment, 571–572
 clinical presentation, 570–571
 diagnostic testing, 571
 differential diagnoses, 571
 etiology and pathophysiology, 569–570
 follow-up care, 573
 history and physical examination of, 571
 incidence and prevalence, 569
 management, 572–573, 573t
 patient education, 574
 prevention of, 572
 risk factors for, 571
 special considerations for women, 574–575
 vulvar changes, in pregnancy, 679
 vulvar intraepithelial neoplasia, types of, 570
 vulva skin conditions
 assessment of, 544–545, 545b, 546b
 differential diagnoses of, 543, 544t
 skin cysts, 545–547
 carbuncles, 546
 epidermoid and sebaceous cysts, 546
 folliculitis and furuncles, 546
 hidradenitis suppurativa, 546–547
 vulvovaginal candidiasis, 404t, 412–417, 413f, 415t
 assessment, 412–414, 414f
 classification, 415t
 complementary and alternative therapies, 415
 differential diagnoses, 414
 emerging evidence, 416
 management, 407–410t, 414–416
 patient education, 416